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ABSTRACT 
  
      Mycoplasma bovis is generally considered the causative pathogen associated with 
Chronic Pneumonia and Polyarthritis Syndrome (CPPS) in feedlot cattle. However, M. bovis 
virulence may vary between strains as it is also isolated from asympytomatic cattle. The 
following study aims to determine the prevalence of M. bovis in the respiratory tract of western 
Canadian cattle using two sampling methods and at two time points following feedlot entry. 
Three study groups were sampled. In the first group nasal swabs (NS) and bronchoalveolar 
lavages (BAL) were taken from 36 clincally healthy cattle at the University of Saskatchewan 
feedlot at both 14 and 90 days on feed (DOF).  In a second experiment, NS were taken from 56 
animals upon arrival at a commercial feedlot and one week to three months later upon treatment 
for respiratory disease.  Lung and joint tissue swabs were collected at necropsy from a third 
group of 19 animals with CPPS clinical pathology originating in 10 different western Canadian 
feedlots.  All samples were selectively cultured for Mycoplasma spp. DNA was extracted from 
isolated putative Mycoplasma colonies and amplified with universal 16S rRNA gene primers for 
identification. Amplified Fragment Length Polymorphism (AFLP) was used to genetically 
differentiate M. bovis positive isolates. More M. bovis was isolated from NS than BAL and M. 
bovis prevalence increased with DOF in the feedlot in both the University of Saskatchewan and 
commercial feedlot trials. Three genetically distinct clusters (A, B, and C) were isolated from the 
necropsy group. Two of these clusters were primarily associated with isolates collected from 
feedlot cattle and one strain was exclusively found in CPPS-associated mortalities. No 
significance difference in the prevalence of M. bovis strains was observed between different days 
on feed or sampling methods.  It was concluded that either the difference in disease state is a host 
dependent outcome, due to a multi-factorial disease complex, or the AFLP assay was not 
sensitive enough to differentiate strains based on virulence.  
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1.0 INTRODUCTION  
Mycoplasma bovis is an important pathogen in the feedlot industry from both economic 
and welfare concerns (Nicholas and Ayling, 2003). Previous research has shown that M. bovis 
may afflict cattle with a variety of diseases such as mastitis, otitis media, keratoconjuctivitis and 
chronic pneumonia and polyarthritis syndrome (Alberti et al., 2006; Gagea et al., 2006; Maeda et 
al., 2003). Combined, all of the clinical manifestations of this pathogen are estimated to cost $32 
million dollars annually to the American cattle industry and €144 million to the European 
industry (Nicholas and Ayling, 2003).  
The M. bovis condition of particular interest to the feedlot industry is Chronic Pneumonia 
and Polyarthritis Syndrome (CPPS). Mycoplasma bovis has been shown to cause pneumonia in 
feedlot cattle and as the bacteria can resist many of the traditional treatments for pneumonia in 
the feedlot, this may develop into a CPPS, which is defined by the simultaneous presence of both 
persistent pneumonia and arthritis in at least one joint (Krysak, 2006; Nicholas and Ayling, 
2003). CPPS can take weeks or months between onset of disease and either death, euthanasia, or 
recovery (Krysak, 2006; Pfützner, 1990). This long disease process confronts the producer with a 
great deal of labour associated costs, veterinary bills, and other disease related expenses, as well 
as significant welfare concerns in regards to the animal (Nicholas and Ayling, 2003).   
Mycoplasma bovis has been isolated from the respiratory tracts of healthy cattle; 
therefore, there has been some speculation regarding the pathogenicity of the bacteria.  Further, 
in many cases, cattle ailing from pneumonic symptoms that test positive for M. bovis also test 
positive for many other bacteria associated with pneumonia in cattle (Blackburn et al., 2007). It 
is therefore, still unclear whether M. bovis is the primary causative agent initiating the disease or 
a secondary factor to one of the many other organisms associated with respiratory disease in 
cattle. However, pneumonic conditions have been established both in gnotobiotic and 
conventional cattle inoculated with M. bovis (Arcangioli et al., 2007; Pourmat et al., 2001; 
Thomas et al., 1986).  Pourmat et al (2001) showed that inoculation of M. bovis in 
conventionally reared calves not only resulted in these calves showing clinical signs suggestive 
of pneumonia, but also increased the numbers of another bacterium, Pasteurella multocida, 
which has been associated with bovine respiratory disease, suggesting that it was indeed the 
primary causative agent at least in this multifactorial scenario. Another study examined not only 
M. bovis, but many other agents thought to be associated with bovine respiratory disease, and 
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found that in cattle afflicted with bovine respiratory disease, M. bovis was the most common 
pathogen present (Arcangioli et al., 2007).  Finally, in a survey of the prevalence of M. bovis in 
stocker and backgrounding operations it was noted that cattle testing positive for M. bovis in 
nasal swabs were more likely to exhibit symptoms, such as fever and mucopurulent nasal 
discharge, clinical signs indicative of respiratory disease (Wiggins et al., 2007).   
Members of the Mycoplasma genus are extremely small organisms lacking cell walls and 
are therefore, resistant to many antibiotics, such as the β-lactams, that target bacterial cell wall 
structures (Francoz et al., 2005; ter Laak et al., 1993). M. bovis has also shown resistance to 
other classes of antibiotics often used in feedlots such as many of the tetracyclines and may be 
developing resistance to even more antibiotics, which were at one time effective (Francoz et al., 
2005; ter Laak et al., 1993). Therefore, M. bovis is often associated with CPPS as the pathogen 
survives antibiotic treatments commonly used for pneumonia in feedlots.  
Successful techniques for diagnosis of M. bovis as the causative agent of pneumonia may; 
therefore, be of great importance to the treatment of pneumonia and the prevention of CPPS, as 
antibiotics must be chosen, which are effective for M. bovis in those animals testing positive for 
the pathogen. Research suggests that samples taken by bronchoalveolar lavages are more 
effective for M. bovis screening than nasal swabs, as M. bovis is thought to be a colonizer of the 
lower respiratory tract (Thomas et al., 2004). These samples have been tested for specific 
Mycoplasma spp. using ELISA assays or sequence analysis of PCR amplified universal target 
genes (Ayling et al., 1997; Butler et al., 2001; Dénes et al., 2003).  
While successful identification of M. bovis and appropriate antibiotic administration may 
treat specific cattle already ailing from CPPS on a case to case basis, this treatment would be 
largely ineffective for elimination of M. bovis from a pen of feedlot animals or a herd of cows 
and calves. This is because M. bovis also colonizes healthy animals, which may shed the 
organism via nasal secretions to their cohorts (Butler et al., 2001). The addition of new cattle into 
a feedlot, as is done in western Canadian feedlots, has been shown to increase the likelihood of 
identifying M. bovis in penmates (Butler et al., 2001).  Prevention of M. bovis induced CPPS, 
using effective antibiotics or other approaches is; therefore, vital to disease control.   
The ineffectiveness of prophylactic antibiotics in CPPS prevention has made M. bovis 
vaccination research of great interest. However, the variability of M. bovis surface proteins has 
made successful vaccine development very difficult (Perez-Casal and Prysliak, 2007). 
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Development of an M. bovis vaccine effective against all virulent strains has also been hindered 
by the lack of research available regarding pathogenic strains and their virulence factors as 
antigenic targets (Perez-Casal and Prysliak, 2007). Vaccines are available for M. bovis induced 
mammary infections and research is ongoing for CPPS associated M. bovis vaccines; however, 
these vaccines have produced ineffective results in clinical trials (Boothby et al., 1986; Chima et 
al., 1981; Nicholas and Ayling, 2003; Perez-Casal and Prysliak, 2007; Maunsell and Donovan, 
2009). Therefore, a better understanding of the virulent strains and virulence associated genes in 
M. bovis could greatly benefit the development of efficacious commercial vaccines.  
While M. bovis studies have been conducted in feedlots and stocker/backgrounding 
operations in other areas of the world such as Europe (Arcangioli, et al., 2007; Blackburn et al., 
2007), the United States (Wiggins et al., 2007) and Eastern Canada (Gagea et al., 2006), an 
extensive survey of western Canada has not been conducted; therefore, the prevalence of M. 
bovis as a possible causative agent of CPPS in this region is unknown. There are also many 
strains of M. bovis and these different strains may be responsible for different conditions in the 
animal (Blackburn et al., 2007; Miles et al., 2005). For example, the strain that causes mastitis in 
dairy cattle is not the same strain that causes pneumonia in feedlot cattle (Biddle et al., 2005). 
Conceivably the strain that causes pneumonia may be different from the strain that allows for 
dissemination to the joint and development of CPPS. Therefore, determining the strains of M. 
bovis associated with CPPS in western Canadian feedlots would also increase the understanding 
of the disease and its prevention in this area of the world.  
The proposed study will aim to establish strain differentiation methods for M.bovis; 
utilize these methodologies to identify strains common to cattle with CPPS clinical pathology at 
necropsy; determine the prevalence of M. bovis strains in healthy feedlot cattle and cattle treated 
for respiratory disease; and compare the Mycoplasma spp. populations in the upper and lower 
respiratory tracts of healthy cattle. This will allow us to test the hypothesis that a unique strain of 
M. bovis is associated with CPPS.   
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2.0 LITERATURE REVIEW 
 2.1 Mycoplasma bovis taxonomy and general characteristics 
   The genus Mycoplasma belongs to the Mollicutes class in the phylum Firmicutes, which 
encompasses many low G+C gram positive bacteria (Sirand-Pugnet et al., 2007b; Weisburg et 
al., 1989; Woese et al., 1980). The Mollicutes are thought to have evolved from more typical 
Gram positive low G+C bacteria in a regressive manner involving large-scale genome reduction. 
The class was actually named ‘Mollicutes’, Latin for ‘soft skin’, as their small genome size 
results in an inability to produce peptidoglycan cell wall. This incredibly small genome size also 
lacks many other genes involved in critical biochemical pathways. Therefore, Mollicutes are 
generally considered parasitic organisms, requiring their host organisms to provide essential 
nutrients (Sirand-Pugnet et al., 2007b; Weisburg et al., 1989; Woese et al., 1980). The inability 
of Mollicutes to synthesize essential nutrients also makes them extremely hard to culture; 
however, growth of many species is possible at 37°C on complex growth medias (Hannan, 
2000). Replication of these Mollicutes occurs by binary fission like prokaryote; however, the 
mechanisms are not yet well understood (Miyata and Seto, 1999; Razin et al., 1998). Also recent 
research suggests that at least in some Mollicutes there is much higher horizontal gene transfer 
rate than thought in early studies; therefore, some members of this class may have retained or 
acquired sexual competence (Sirand-Pugnet et al., 2007a).  
   There are about 200 species of Mollicutes, over 100 of which belong to the Mycoplasma 
genus (Trachtenberg, 2005; Weisberg et al., 1989). The first isolation of a Mycoplasma was in 
1896 at Pasteur institute (Nocard and Roux, 1896). The organism was cultured from cattle 
suffering from arthritis and pleuropneumonia (Nocard and Roux, 1896). Mycoplasma spp., 
however, inhabit a wide array of host organisms, colonizing over 180 species in plants and 
animals (Weisberg et al., 1989). They were until recently thought to be exclusively extracellular 
pathogens, simply adhering to specific tissues and organs in the host (Weisburg et al., 1989; 
Woese et al., 1980). However, internalization of Mycoplasma spp. into host cells is now being 
studied and mechanisms involving adhesion induced specific changes to microtubule and 
microfilament structure of the host cytoskeleton have been discovered in specific species (Ueno 
et al., 2008; Winner et al., 2000; Yavlovich et al., 2004; Yavlovich et al., 2006). Mycoplasma 
colonization in animals is often pathogenic, causing a wide range of physiological manifestations 
ranging from various respiratory, cardiovascular, ocular, reproductive, urogenital, central 
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nervous system, skin and joint conditions (Alberti et al., 2006; Byrne et al., 1999; Gagea et al., 
2006; Lu and Rosenbusch, 2004; Maeda et al., 2003). These conditions are also difficult to treat 
and prevent as Mycoplasma spp. are inherently resistance to many antibiotics and have several 
methods of modifying and evading the immune system (Allen et al., 1992; Behrens et al., 1996, 
Haines et al., 2001; Radaelli et al., 2009; Rosengarten et al., 1994; Vanden Bush and 
Rosenbusch, 2003). Therefore, ongoing research into Mycoplasma pathogens is of great 
importance to the livestock industries currently trying to treat and prevent Mycoplasma-
associated disease.       
  
 2.2 Mycoplasma bovis and Chronic Pneumonia and Polyarthritis Syndrome (CPPS)  
   There is speculation regarding the relevancy of M. bovis as a causative agent of CPPS as 
M. bovis is also isolated from healthy animals (Allen et al., 1991; 1992; Hirose et al., 2003; 
Rosendal and Martin, 1986; Sachse et al., 2009; ter Laak et al., 1992b; Thomas et al., 2002; 
Wiggins et al., 2007). However, several studies have concluded that the presence of M. bovis or 
M. bovis antigens is highly associated with both the symptoms and clinical pathology of CPPS in 
cattle at necropsy (Booker et al., 2008; Gagea et al., 2006; Haines et al., 2001; Maeda et al., 
2003; Radaelli et al., 2008; Rodríguez et al., 1996; Wiggins et al., 2007). There has also been 
some conjecture that M. bovis is an opportunistic pathogen that takes advantage of lesions caused 
by primary infection with other respiratory pathogens, as it is often found associated with other 
well established pathogens in cases of feedlot respiratory disease (Blackburn et al., 2007; Booker 
 et al., 2008; Fulton et al., 2009; Martin et al., 1999; Shahriar et al., 2002; Thomas et al., 2002).  
However, cattle afflicted with CPPS have been found to carry no other respiratory pathogens but 
M. bovis. In both conventional and gnotobiotic experimental inoculations in calves, M. bovis was 
able to induce CPPS clinical symptoms (Allen et al., 1992; Arcangioli et al., 2008; Haines et al., 
2001; Khodakaram-Tafti and López, 2004; Poumarat et al., 2001).  This suggests that M. bovis 
may not require pre-existing respiratory disease and a multifactorial scenario to be pathogenic.  
Poumarat et al (2001) found that not only did M. bovis inoculation of calves result in an increase 
in clinical signs suggestive of pneumonia, but also increased the numbers of another bacteria, 
Pasteurella multocida, that has been associated with bovine respiratory disease, suggesting that 
M. bovis may even be capable of providing the primary infection for common multifactorial 
respiratory disease in calves.  
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  2.2.1 Mycoplasma bovis and CPPS prevalence  
   Although there have been many studies regarding the prevalence of M. bovis in feedlots 
conducted in Europe, Asia and North America, the results differ considerably from under 5% to 
near 100% of feedlot calves colonized with M. bovis  (Allen et al., 1991; 1992; Angen et al., 
2009; Arcangioli et al 2008; Catry et al., 2008; Haines et al., 2001; Hirose et al., 2003; Rosendal 
and Martin, 1986; Sachse et al., 2009; ter Laak et al., 1992a; ter Laak et al., 1992b; Thomas et 
al., 2002; Martin et al., 1999; Wiggins et al., 2007). The differences may be due to the large 
difference in geographical location; however, even prevalence studies conducted in the same 
area differ. Canadian studies have reported anywhere from 46-100% of animals with respiratory 
disease (Allen et al., 1991; 1992; Haines et al., 2001) and from 5-52% of healthy cattle colonized 
with M. bovis (Allen et al., 1991; 1992; Rosendal and Martin, 1986, Martin et al., 1999).  
Differences in M. bovis prevalence recorded in similar geographical regions could be due to 
differences in year or numerous other variables, which differ among the studies conducted. 
Enumeration methods widely vary and this may be another cause for differences between M. 
bovis prevalence studies. The Canadian studies that enumerated serum M. bovis antibody levels 
(Rosendal and Martin, 1986; Martin et al., 1999) showed much lower prevalence of M. bovis in 
both healthy animals and those with respiratory disease than the studies that used 
immunohistochemistry in lesions (Haines et al., 2001) or fluorescent antibody detection of 
culture (Allen et al., 1991; 1992) to enumerate animals with M. bovis at necropsy (Haines et al., 
2001). Other studies outside of Canada have also used culture techniques that may be followed 
up by molecular, or immunoblotting typing methods to identify M. bovis (Angen et al., 2009; 
Arcangioli et al 2008; Catry et al., 2008; Hirose et al., 2003; Sachse et al., 2009; ter Laak et al., 
1992a; ter Laak et al., 1992b; Thomas et al., 2002; Wiggins et al., 2007).  
   The differences in sampling method have been shown to impact enumeration of M. bovis. 
For instance in several studies it was suggested that M. bovis prevalence, as determined by nasal 
swab sampling, was higher than as determined by bronchoalveolar lavage (Allen et al., 1992; 
Catry et al., 2008), while in one study the opposite was observed (Allen et al., 1991). In a 
Canadian study conducted by Haines et al in 2001, 80% of cattle with chronic pneumonia were 
identified as positive for M. bovis from lung and joint tissue samples while in a study conducted 
by Allen et al (1991), 46% of the animals with acute pneumonia tested M. bovis positive from 
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nasal swabs and 61% from bronchoalveolar lavages. The time of sampling may also affect 
results. The previous examples may also differ in prevalence as the Haines et al. study sampled 
animals upon necropsy while the Allen et al. study sampled animals at 28 days on feed with 
acute pneumonia. Furthermore, several groups of researchers found that M. bovis prevalence was 
increased with length of time that animals had been in the feedlot (Allen et al., 1992; Rosendal 
and Martin et al., 1986). In a study conducted by Allen et al (1992) M. bovis positive nasal swab 
or bronchoalveolar lavage samples in animals with chronic unresponsive respiratory disease 
increased from between 45-60% to 100% in a twelve day period in the feedlot. 
   The culturing method may also largely impact the results of M. bovis prevalence 
research. M. bovis is slow-growing and fastidious; therefore, the results may differ depending on 
conditions and time of culture (Hannan, 2000). The prevalence of M. bovis in studies where other 
respiratory pathogens are also being cultured may result in an underestimation of M. bovis as 
other bacterial pathogens are faster growing with fewer nutritional requirements; therefore, they 
may be cultured first (Hannan, 2000; Nicholas and Ayling, 2003). 
   While the exact prevalence of CPPS in feedlots is still not well understood, several 
studies have found that in the bovine respiratory disease complex M. bovis was one of  the most 
common pathogens present (Allen et al., 1992; Arcangioli et al., 2008;  Catry et al., 2008). 
Therefore, while quantitative data regarding M. bovis colonization and CPPS in feedlots may be 
difficult to obtain, the evidence suggests a high prevalence of M. bovis in feedlot respiratory 
disease worldwide.  
 
   
2.2.2 CPPS clinical manifestations in the feedlot 
   The initial symptoms of CPPS are often indistinguishable from undifferentiated fever 
common to feedlot calves in the first months on feed (Adgeboye et al., 1995; Booker et al., 2008; 
Dyer et al., 2008; Krysak, 2006). Respiratory symptoms such as dyspnoea, anorexia, fever and 
general malaise are common clinical findings in new arrivals to the feedlot (Adgeboye et al., 
1995; Booker et al., 2008; Dyer et al., 2008; Krysak, 2006). However, in cases of CPPS, 
common antibiotic treatment for undifferentiated respiratory disease will not improve the 
condition and the pneumonia often persists (Adgeboye et al., 1995; ter Laak 1992a). If signs of 
arthritis, including lameness, abnormal posture and reluctance to move did not exist prior to 
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treatment for respiratory disease, they often develop as the M. bovis pneumonia progresses to 
CPPS (Adgeboye et al., 1995; Dyer et al., 2008; Krysak, 2006). Often cattle will succumb to 
total recumbancy and die of severe dyspnoea, if not first euthanized (Dyer et al., 2008; Gagea et 
al., 2006; Haines et al., 2001; Krysak, 2006; Maeda et al., 2003).  
   Mycoplasma bovis pneumonia is associated with unique clinical pathology (Haines et al., 
2001; Krysak, 2006; ter Laak et al., 1992a). Other pneumonia associated bacterial pathogens 
common to feedlots such as Histophilus somni and Mannheimia haemolytica cause 
fibrinosupprative bronchopneumonia characterized with fibrinous purulent liquid material and 
non-raised red to pink irregular shaped foci of coagulative necrosis while M. bovis causes 
chronic cranioventral bronchopneumonia characterized by white, circular friable foci with 
caseous necrosis, a more solid form of cheese-like purulence (Fulton et al., 2009; Gagea et al., 
2006; Khodakaram-Tafti and López, 2004; Rodríguez et al., 1996). The occurence of arthritis in 
one or several joints in CPPS cases differentiates it from other bacterial pneumonias.  The 
arthritis present in CPPS cases is characterized by joint distension, hyperplasic synovium, 
increased synovial fluid, presence of thick yellow fibrinous purulent exudates. Occasionally 
infection spreads to tendon sheaths, bursa and joint capsules and caseous necrosis foci develop in 
surrounding tissues (Dyer et al., 2008; Gagea et al., 2006; Krysak, 2006).  
   Studies utilizing immunohistochemistry have not only found a close association with M. 
bovis antigens and the foci of caseous necrosis in cranioventral bronchopneumonia characteristic 
of CPPS, but have also found more discerning characteristics between CPPS pneumonia lesions 
and those formed from other bacterial infections (Gagea et al., 2006; Haines et al., 2001;  
Rodríguez et al., 1996). The necrotic foci of M. bovis infections contain eosinic material with 
necrotic leukocytes, especially macrophages present in the periphery, while lesions from 
Mannheimia haemolytica for instance show basophilic bands around the necrotic foci and more 
neutrophils around the periphery (Gagea et al., 2006; Khodakaram-Tafti and López, 2004; 
Rodríguez et al., 1996). Mannheimia haemolytica associated necrotic foci also show less 
degradation of pulmonary architecture than those caused by M. bovis (Gagea et al., 2006). While 
the lung pathology at both visual and cellular levels does appear to be unique to the causative 
agent, it should be noted that often several bacterial pathogens colonize concurrently (Allen et 
al., 1991; Arcangioli et al., 2008; Gagea et al., 2006; Haines et al., 2001; Martin et al., 1999; 
Poumarat et al., 2001). Therefore, a single pneumonic feedlot calve may have an overlap of 
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lesion types, locations and leukocyte accumulation associated with these various pathogens 
(Adgeboye et al., 1995; Gagea et al., 2006, Khodakaram-Tafti and López, 2004).  
 
  2.2.3 Treatment challenges 
   Treatment of M. bovis is often complicated as Mycoplasma spp. are either resistant or 
gaining resistance to many of the antibiotics commonly used in the treatment of feedlot 
respiratory diseases. Therefore, the standard treatments for feedlot respiratory diseases may be 
changing as a result of the high prevalence of M. bovis being isolated from feedlot cattle with 
respiratory disease symptoms. The use of β-lactam group, including ampicillin, penicillin and 
ceftiofur, in commercial feedlots has been shown to be extremely ineffective in treating 
respiratory disease where M. bovis is a causative factor (Allen et al., 1992; Haines et al., 2001). 
This is due to the fact that β-lactam antibiotics inhibit cell wall synthesis of bacteria. As 
Mycoplasma spp. inherently have no cell wall the β-lactam antimicrobials have no mode of 
action on this genus of bacteria. Other groups of commonly utilized feedlot antibiotics such as 
the tetracyclines including oxytetracycline, tetracycline and chlorotetracycline and the 
macrolides including tilmicosin, tylosine, and erithromycin, have been found to be potentially 
efficacious in a few in vivo studies where calves were treated early (Bednarek et al., 2003; 
Godinho et al., 2005a; 2005b; Musser et al., 1996; ter Laak et al 1993). However, many studies 
indicate low susceptibility of M. bovis in vivo and in vitro to these groups of antibiotics, 
suggesting that perhaps M. bovis is capable of acquiring resistance to these antimicrobials 
(Cooper et al., 1993; Francoz et al., 2005; Godinho et al., 2008; Gerchman et al., 2009; Hannan 
et al., 1997; Hirose et al., 2003; Rosenbusch et al., 2005; ter Laak et al., 1993; Vogel et al., 
2001). Mycoplasma bovis has been found to be highly resistant to sulfonamides group including 
sulfadoxine and the aminoglycosides including spectinomycin, streptomycin and gentamicin, in 
the majority of in vivo and in vitro studies (Allen et al., 1992; Francoz et al., 2005; Gerchman et 
al., 2009; Haines et al., 2001; ter Laak et al., 1993; Thomas et al., 2003b; Vogel et al., 2001). 
   The literature suggests that the antimicrobials with the highest potential for treatment of 
M. bovis in feedlot cattle belong to the fluoroquinolones (Francoz et al., 2005; Hannan et al., 
1997; Hirose et al., 2003; Rosenbusch et al., 2005; Stipkovits et al., 2005; Thomas et al., 2003b). 
While Hannan et al (1997) found that M. bovis appears to be highly resistant to one member of 
this group, flumequire, the other antibiotics in this classification, such as, enrofloxacin have 
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shown promising antimicrobial activity in Minimum Inhibitory Concentration (MIC) studies in 
vitro and significant decreases in respiratory disease clinical symptoms and M. bovis 
colonization in vivo (Francoz et al., 2005; Hannan et al., 1997; Hirose et al., 2003; Rosenbusch et 
al., 2005; Stipkovits et al., 2005; Thomas et al., 2003b). There are also a few antibiotics not 
classified in any of the aforementioned groups such as tiamulin, valnemulin, lincomycin, and 
florfenicol, which have shown potential as effective antimicrobials against M. bovis associated 
respiratory disease (Catry et al., 2008; Hannan et al., 1997; Hirose et al., 2003; Rosenbusch et a, 
2005; Stipkovits et al., 2001; 2005).  Current research also indicates that treatment with either 
steroidal or non-steroidal anti-inflammatory drugs in conjunction with antimicrobial therapy may 
be more efficacious in the treatment of bronchopneumonia than antimicrobial therapy alone; 
therefore, these drugs should be considered for treatment of M. bovis associated pneumonia 
(Bednarek et al., 2003).  
   It should be noted that many of these antimicrobial susceptibility studies for M. bovis are 
conducted in vitro and up until the year 2000 there were no established standardized guidelines 
for in vitro antimicrobial susceptibility testing in Mycoplasma species (Hannan, 2000). As 
Mycoplasma spp. are very slow growing and fastidious, the differences in laboratory techniques 
before 2000 could have resulted in drastically different MIC values between studies of the same 
antimicrobial (Hannan, 2000). Additionally, in vitro antimicrobial susceptibilities of field 
isolates have been found to be much lower than susceptibilities of type strains in several studies 
(Hannan et al., 1997; Hirose et al., 2003; ter Laak et al., 1993). Nevertheless, in vitro study 
results for specified antimicrobials are often in poor agreement with in vivo studies, even if 
conducted by the same group (Godinho et al., 2005a; 2005b; 2008). This suggests that in vitro 
studies may be a poor reflection of antimicrobial efficacy in the field.  
   As for treatment recommendations, it was found in one study that the susceptibilities 
between field strains taken from different geographical regions may vary significantly; therefore, 
it was suggested that antimicrobial testing be conducted for M. bovis strains in specific regions 
before antimicrobial treatment recommendations be made (Gerchman et al., 2009). Also the 
studies showing promising results of antimicrobial therapy in vivo all treated calves within the 
1st 10 days of infection; therefore, the efficacy of these antimicrobials at later disease stages is 
unknown and may differ greatly from results seen with early treatment (Godinho et al., 2005a; 
2005b; Gourlay et al., 1989; Poumarat et al., 2001; Stipkovits et al., 2001; 2005). Therefore, 
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when utilizing literature results for selection of efficacious M. bovis antimicrobials, the 
experimental design, laboratory techniques, strain selection, and geographical location must be 
considered.  
 
  2.2.4 Prevention challenges: prophylactic antibiotics and vaccination 
  Antibiotic prophylaxis has been shown in many field studies to be ineffective in 
prevention of M. bovis respiratory disease (Allen et al., 1992; Booker et al., 2008; Wiggins et al 
2007). However, most of the antibiotics in these cases belonged to classes like the β-lactams, 
macrolides or aminoglycosides, which are often ineffective in treatment of M. bovis diseases. 
However, several studies have provided evidence that antimicrobial prophylaxis with florfenicol, 
valnemulin or tilmicosin may reduce M. bovis colonization and symptoms of respiratory disease 
in young cattle (Catry et al., 2008; Gourlay et al., 1989; Stipkovits et al., 2001). Therefore, there 
may be some potential for antibiotic prophylaxis if M. bovis is considered when the types of 
antibiotics for respiratory disease prophylaxis are chosen.  
   Areas of the world such as the European Union are now banning the use of prophylactic 
antibiotics in attempts to reduce antibiotic resistance in zoonotic pathogens. Therefore, 
vaccination of M. bovis would be a preferable prevention method. While there are a few 
commercially available vaccines marketed in the United States of America such as Pulmo-
GuardTM MpB (Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO), Mycomune® R 
(Agrilabs®, St. Joseph, MO) and MYCO-BAC® B (Texas Vet Lab, San Angelo, Tx), the 
efficacy has been questioned in several highly cited reviews as there is often no available 
literature to support the claims made by the vaccine manufacturer (Maunsell and Donovan, 2009; 
Nicholas et al., 2009).  While vaccine production has been ongoing for 20 years with many 
potential vaccines having been described in the literature, the efficacy of these vaccines in the 
field is highly questionable. There are several reasons for the difficulties in vaccination 
production. Often these vaccines are either a killed or inactivated single strain of M. bovis or a 
single antigen (Calloway et al., 2008; Cho et al., 2008, Maunsell et al., 2009, Nicholas et al., 
2002). However, M. bovis surface antigens have been shown to be highly variable; therefore, 
these vaccines that are designed around a single M. bovis strain may have very low efficacy in 
eliciting an immune response that would protect against other strains or even the same strain 
after a given amount of time. A study by Maunsell and Donovan (2009) tested a commercially 
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available M. bovis bacterin vaccine for efficacy in a field trial and found that the vaccine had no 
effect on serum antibody titres, respiratory disease outcome, weight gain, mortality or M. bovis 
colonization of the upper respiratory tract. While this vaccine may have tested well in the initial 
clinical trials conducted by the manufacturer, its efficacy after time or in field trials with diverse 
populations of M. bovis strains was low, most likely due to the high heterogeneity and variability 
of M. bovis antigens.  
   Recent studies have been conducted in attempts to find homologous antigens in diverse 
M. bovis populations. Behrens et al (1996) discovered a surface protein that was found to be the 
main antigen recognized during M. bovis infection and was unrelated to the common class of 
Variable Surface Proteins (VSP) in that it contained no repetitive structures common to these 
highly variable proteins, suggesting that it may be more stable. However, it was observed that 
this surface protein also undergoes a high rate of size and phase variation; therefore, it is an 
equally unstable antigen as the variable surface proteins. Perez-Casal and Prysliak et al (2007) 
investigated glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a vaccine target as it has 
successfully been used in vaccine production for other pathogenic bacteria. GAPDH was 
suggested to have a possible involvement in adherence and low antigenic variation in M. bovis. 
Also when cattle were inoculated with M. bovis GAPDH they mounted a strong antibody 
response, suggesting this may be an effective vaccine target. Further research into potential 
antigen targets with low phase variation is necessary; however, if stable antigen targets are 
studied, efficacious vaccine preventative methods may be possible in the future. Unfortunately 
for now good management practices including appropriate identification, isolation and early 
treatment of CPPS afflicted animals may be the best prevention method.  
 
 2.3 Variable pathogenicity of Mycoplasma bovis 
   Mycoplasma related diseases are often difficult to fully define epidemiologically. Species 
of Mycoplasma-associated with disease in one animal can often also be isolated from healthy 
animals. Thus, colonization with Mycoplasma does not necessarily lead to disease in the animal. 
Strain differentiation studies have found that strains colonizing various infection sites can differ 
(Biddle et al., 2005). For instance, the strains of M. bovis that cause respiratory disease are not 
necessarily the strains that cause mastitis (Biddle et al., 2005). Also, pathogenicity can vary 
between strains of M. bovis (Adgeboye et al., 1995; Khan et al., 2005; Lu and Rosenbusch, 
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2004). This suggests that while there may be conditions that are more favourable to disease onset 
and progression, the difference in disease status between animals colonized with M. bovis may 
be attributable to variation in pathogenicity between strains of M. bovis. Therefore, the 
identification of M. bovis virulence mechanisms may be an important step in understanding the 
differences between the aetiology of M. bovis associated diseases and seemingly commensal 
colonization.  
The ability of M. bovis to adhere to host cells appears to vary among strains and a strong 
link between adherence and pathogenicity in Mycoplasmas has been observed in several studies 
(Powell et al., 1976; Taylor-Robinson et al., 1981; Papazis et al., 2000). Adherence rates of M. 
bovis are significantly decreased in non-pathogenic strains when compared to strains recovered 
from cases of clinical mastitis (Thomas et al., 2003a). Adherence of M. bovis also appears to be 
tissue specific as adherence to endothelial cells has been observed to be significantly higher than 
to other cell types (Thomas et al., 2003a). It has also been observed that inhibition of adherence 
to one host cell type, for example by blocking membrane proteins with the addition of 
monoclonal antibodies, may not inhibit adherence to other tissues and cell types (Thomas et al., 
2003c). Therefore, one possible explanation for the different disease outcomes associated with 
different strains is that there may be several mechanisms for adherence to different tissues that 
vary between strains or are expressed differently in a single strain under varaiable conditions 
(Papazis et al., 2000; Powell et al., 1976; Taylor-Robinson et al., 1981; Thomas et al., 2003c). 
Pathogenic strains of M. bovis elicit specific immune responses in the host that not only 
benefit tissue degradation; therefore, nutrient acquisition and systemic infection opportunities for 
the pathogen, but also allow the pathogen to evade the immune system causing chronic infection 
(Geary et al., 1981; Lu and Rosenbusch, 2004; Thomas et al., 1986; Thomas et al., 1990; 
Thomas et al., 1991; Vanden Bush and Rosenbusch, 2002; 2003). Extracellular pathogens such 
as M. bovis often elicit a type 2 T-helper cell (Th2) regulated humoral based immune response 
characterized by the activation of antibody producing B-cells (Howard and Gourlay, 1983; 
Vanden Bush and Rosenbusch, 2003). The cytokine IL-4 is involved in Th2 activation of IgG1 
immunoglobulin producing B-cells and the upregulation of both IL-4 and IgG1 has been 
observed in M. bovis infections. However, the Th2 response observed in M. bovis infections is 
only skewed not polarized, as some activation of Th1 induced cellular immune pathways has 
also been observed. The up-regulation of a cytokine known as interferon-gamma (IFN-ɣ) as well 
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as the production of IgG2 immunoglobulins are characteristic of Th1 regulated immunity and 
have also been observed in the host in response to M. bovis infection. The immune response is 
both pathogen induced and host dependent. The Th2 immune response has been shown to 
weaken the lung cell junctions and suppress wound healing in lung tissue while the Th1 response 
has been shown to sensitize alveolar cells to apoptosis. A skewed response may be beneficial to 
the host as a polarized Th1 or Th2 response could result in severe lung damage while causing 
dissemination or further access of the pathogen to the host. The Th2 skewed response is most 
likely elicited by the host to prevent severe lung damage. However, the Th2 skewed response 
still provides some tissue damage, facilitating M. bovis nutrient acquisition and further infection, 
while also skewing the immunoglobulin production towards IgG1 as opposed to the superior 
opsonin IgG2. Consequently, the Th2 skewed response may benefit the longevity of M. bovis; 
therefore, the chronicity of the disease (Howard and Groulay, 1983; Van den Bush and 
Rosenbusch, 2003).   
Up-regulation of the inflammatory response is also a common observation upon adhesion 
of pathogenic M. bovis strains to endothelial cells and some inflammatory cytokines appear to be 
linked with pathogenicity among M. bovis strains (Geary et al., 1981; Jungi et al., 1996; Lu and 
Rosenbusch, 2004). Chemotaxis and transmigration of mononuclear cells has been observed in 
epithelial cells exposed to pathogenic M. bovis strains. Subsequently up-regulation of the 
proinflammatory cytokines such as TNF-ɑ, IL-1, IL-6 and IL-8 that are produced by 
macrophages and neutrophils has also been observed in M. bovis. Geary et al (1981) also 
described an excreted toxin with pro-inflammatory effects. The inflammation is thought to be an 
immunomodulatory effect of M. bovis that increases adhesion to and permeation of endothelial 
cells, which is important in progression of M. bovis-associated diseases to systemic infection 
(Geary et al., 1981; Jungi et al., 1996; Lu and Rosenbusch, 2004).  
 While the host’s immune response elicited by the immunomodulatory effects of M. bovis 
may improve access to nutrient acquisition and systemic spread, they also activate many 
phagocytic cells and lymphocytes that may increase the hosts chances of clearing the infection 
(Carroll et al., 1977; Howard and Gourlay, 1983; Howard et al., 1976; Howard et al., 1986; Lu 
and Rosenbusch, 2004; Vanden Bush and Rosenbusch, 2003). However, M. bovis has several 
mechanisms of evading the host immune response (Behrens et al., 1996; Le Grand et al., 1996; 
Lysnyansky et al., 1996; Lysnyansky et al., 1999; Sachse et al., 2000; Thomas et al., 1986; 
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Thomas et al., 1990; Thomas et al., 1991; Vanden Bush and Rosenbusch, 2002; 2003). While 
incubation of endothelial cells with M. bovis antigen has been observed to induce the activation 
of phagocytic leukocytes some mechanism in viable M. bovis bacteria enables it to suppress and 
inhibit phagocytic cells (Howard et al., 1976, Thomas et al., 1991; Vanden Bush and 
Rosenbusch, 2003; Vanden Bush and Rosenbusch, 2004). Induction of lymphocyte apoptosis, as 
well as inhibition of lymphocyte mitosis, neutrophil activation and expression of lympho-
inhibitory peptides by M. bovis has been observed (Thomas et al., 1990; Thomas et al., 1991; 
Vanden Bush and Rosenbusch, 2002; Vanden Bush and Rosenbusch, 2004). The evasion 
mechanisms of M. bovis from phagocytes and lymphocytes are important to the virulence of the 
pathogen and the chronic disease state.  
The importance of adhesion to the virulence of M. bovis strains has been previously 
described; however, the surface proteins involved in M. bovis adhesion to host cells serve a dual 
role. These surface proteins serve as antigens and serum antibodies specific to these antigens are 
often found in bovine serum after infection (Sachse et al., 2000). However, these antigens, 
including a class known as the VSP, are coded with reiterated sequences that undergo high rates 
of chromosomal rearrangement that cause both size and phase shift when these proteins are 
expressed (Behrens et al., 1996, Le Grand et al., 1996, Lysnyansky et al., 1996; Lysnyansky et al 
1999; Poumarat et al., 1999; Sachse et al., 2009). This allows for a constant change in the 
antigenic phenotype expressed on the M. bovis cell surface that has been shown to effectively 
evade the humoral immune system proteins (Behrens et al., 1996, Le Grand et al., 1996, 
Lysnyansky et al., 1996; Lysnyansky et al., 1999; Poumarat et al., 1999; Sachse et al., 2009). In 
one study chromosomal rearrangements in the VSP coding regions were induced by the presence 
of bovine immunoglobulins specific to a VSP protein and a reverse of these rearrangements was 
observed when the antibodies were removed (Le Grand et al., 1996). This suggests that M. bovis 
has the ability to express variability in surface antigens based on the host immune response and 
effectively evade humoral immunity. While M. bovis does appear to have the ability to suppress 
and inhibit lymphocyte activation, an older study demonstrated that phagocytic cells did have the 
capacity to kill M. bovis if appropriate antibody opsonisation was present (Howard et al., 1976). 
Therefore, the evasion of both the humoral and cell mediated response by M. bovis is vital to the 
survival of this bacteria as a pathogen.  
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Mycoplasma bovis virulence is not yet well understood. However, studies regarding the 
adhesion, immunomodulatory and immune evasive behaviour of pathogenic M. bovis strains 
provide some insight into possible differences between the phenotypes of pathogenic and non-
pathogenic strains. The genes responsible for the described virulence phenotypes may vary 
between M. bovis strains in either presence or expression. Further research involving virulence 
gene typing and molecular strain differentiation is required for a better understanding of the 
variable pathogenicity of M. bovis    
 
 2.4 Identification of Mycoplasmas in epidemiology studies 
  2.4.1 Mycoplasma species identification 
   The earliest of detection methods with any bacterial species were generally culture based. 
While several species of Mycoplasma are non-cultivatable, M. bovis is not one of them. 
Mycoplasma bovis is ideally cultured on Hayflick’s agar or broth, at 37°C in 5% CO2 with 
inclusion of a β-lactam antibiotic to inhibit contamination by other cell wall-bearing bacteria 
(Hannan, 2000). Unfortunately this process takes 3-10 days (Abu-amero et al., 1996; Abu-amero 
et al., 2000; Hannan, 2000; Hayflick, 1965). Once colonies are formed several staining and 
biochemical tests can be employed to determine the species represented. 
   There are several methods of determining that colonies are of the Mycoplasma genus. 
Mycoplasmas fluoresce green when stained with Acridine orange, a DNA binding flurochrome 
and are also stainable via the Dienes method that allows for light electron microscopy 
identification of the genus (Dienes, 1967; Jasper et al., 1984; Rosendal and Valdivieso-Garcia, 
1981). Resistance to the antimicrobials has also been used to distinguish Mycoplasmas from 
other bacteria (Abu-Amero et al., 1996). Sterol requirements are also indicators of which genus 
of Mollicutes may be present; Mycoplasma being in the sterol requiring group (Miles and 
Nicholas, 1998). Further metabolic tests such as carbohydrate fermentation capabilities, alcohol 
metabolism rates, proteolytic and lipolytic activities as well as hydrogen peroxide production 
may then be utilized to distinguish between species (Abu-Amero et al., 2000; Khan et al., 2005; 
Miles and Nicholas, 1998). However, there are a limited number of biochemical and metabolic 
tests that can be performed with Mollicutes as the small genome codes for much fewer genes 
than other Eubacteria (Abu-Amero et al., 2000; Miles and Nicholas, 1998; Sirand-Pugnet et al., 
2007b; Weisburg et al., 1989; Woese et al., 1980). Therefore, these bioactive tests may be 
17 
 
inconclusive as several species react very similarly (Abu-Amero et al., 1996; Abu-Amero et al., 
2000; Dienes et al., 1967; Jasper et al., 1984, Khan et al., 2005; Rosendal and Valdivieso, 1981). 
Alternatively the efficiency at which these tests can identify Mollicutes genus is also affected by 
the variability in metabolic and biochemical behaviours observed between strains within a 
species (Khan et al., 2005).   
   To overcome the unreliability of metabolic test results, serologic methods have been 
developed. In the early stages of Mycoplasma research, tests utilizing hyperimmune serum 
specific to single species were utilized for species differentiation via the Growth Inhibition (GI) 
tests in which the inhibition of bacterial growth when exposed to hyperimmune serum for a 
specific species is measured (Polak-Vogelzang et al., 1978; Stanbridge and Hayflick, 1967). The 
indirect fluorescence test and the indirect peroxidise test in which species specific antibodies are 
produced that are bound with either flourochromes or peroxidase enzymes, respectively, have 
also been utilized to differentiate species of Mycoplasmas in early M. bovis studies (Brank et al., 
1999; Cho et al., 1976; Polak-Vogelzang et al 1978). These methods, while more rapid and 
reliable than metabolic and biochemical testing from culture, are still often inconclusive, difficult 
to read, or time consuming and laborious (Brank et al., 1999; Cho et al., 1976; Polak-Vogelzang 
et al., 1978; Stanbridge and Hayflick, 1967).  
  The enzyme linked immunosorbent assay (ELISA) is an improvement on early 
immunological assays. It involves the absorption of immunoglobulins to a microtiter plate that 
are complementary to the antigen, antibody or protein in question. When the sample is added the 
antigen being tested will bind to the fixed complementary immunoglobulin (Engvall and 
Perlmann, 1971; Heller et al., 1993). Subsequent binding of free floating enzyme linked 
complementary immunoglobulins allows for an enzymatic determination of antigen, antibody or 
protein in question when substrate is added. Washing between each step ensures that color 
change or fluorescence produced when substrate is added is indicative of amount of antigen in 
the sample able to bind to the original plastic bound specific immunoglobulin (Engvall and 
Perlmann, 1971; Heller et al., 1993).  
   While ELISA is more sensitive, rapid, and easier to read than the earlier immunological 
methods there are still some specificity issues between closely related species, such as cross 
reactions between M. bovis and M. agalactiae (Boothby et al., 1981; Ghadhersohi et al., 2005; 
Heller et al., 1993; Thomas et al., 1987). Mycoplasma bovis was originally thought to be a 
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subspecies of M. agalactiae, a causative agent of caprine pneumonia, as the two organisms are so 
close biochemically and metabolically (Askaa and Ernø, 1976). However, M. bovis was 
reclassified as a separate species in 1976 when a DNA-DNA hybridization experiment 
demonstrated a much larger genetic diversity than was previously thought (Askaa and Ernø, 
1976). While M. bovis is distinct enough to be a separate species it is still very closely related to 
M. agalactiae and shares many antigens (Boothby et al., 1981; Ghadhersohi et al., 2005; Heller 
et al., 1993; Mattson et al., 1994; Thomas et al., 1987). Therefore, cross-reactivity is often 
observed between the two species in immunological testing. As Mycoplasma spp. have shown 
specificity to particular hosts the cross-reactivity between the caprine pathogen M. agalactiae 
and the bovine pathogen M. bovis was originally thought to be unimportant in diagnostic assays 
as this would not affect the quality of diagnosis for these diseases in their respective animals 
(Boothby et al., 1981; Ghadhersohi et al., 2005; Heller et al., 1993; Thomas et al., 1987). 
However, some cross-colonization has been observed in rare cases in which M. agalactiae has 
been found to colonize cattle and M. bovis has been observed in goats (Bashiruddin et al., 2005; 
Rodríguez et al., 2000). Therefore, the importance of highly specific assays may not only be 
important to scientific laboratories, but may be of increasing importance to clinical laboratories 
as well.  
   There are a few published variations on the ELISA reaction that have been shown to 
improve specificity between closely related Mycoplasma species. Thomas et al (1987) observed 
that preincubation of bovine serum with heterologous antigens, prior to the M. bovis specific 
ELISA reaction reduced the incidence of cross-reactivity with other bovine pathogens as well as 
M. agalactiae. Another study tested a blocking-ELISA in which positive sera would bind to 
specific M. bovis antigen sites effectively blocking the enzyme bound monoclonal antibody 
population from binding and inducing a color reaction (Ghadhersohi et al., 2005). This 
modification of ELISA increased the specificity and sensitivity of the ELISA reaction to a level 
that was comparable with the very specific and sensitive PCR reactions available at the time. It 
was therefore, suggested that blocking-ELISA methods may be valuable diagnostic tools for M. 
bovis serum antibody levels in cattle (Ghadhersohi et al., 2005).  
   Immunoblotting assays on nitrocellulose membrane filtration paper have been developed 
as another serologic based method (Flores-Gutiérrez et al., 2004; Infante et al., 2002; Poumarat 
et al., 1991; Takahata et al., 1997). Mycoplasma colonies are trapped on nitrocellulose paper 
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with vacuum filtration before specific anti-M. bovis antibodies are applied. Enzyme conjugated 
anti-immunoglobulin antibodies are then added so that the amount of M. bovis can be determined 
qualitatively via an enzyme induced substrate color change. This method has shown to be as 
specific and sensitive as ELISA, which again included some cross-reactivity issues in early 
development between M. bovis and M. agalactiae. However, the studies have suggested that 
immunoblotting assays are much quicker than ELISA and as several samples can be analyzed 
simultaneously these assays are also thought to be high-throughput, which is desirable for 
clinical testing (Flores-Gutiérrez et al., 2004; Infante et al., 2002; Poumarat et al., 1991; 
Takahata et al., 1997).  
   Polymerase chain reaction (PCR) amplification of M. bovis specific gene elements may 
provide an extremely fast, sensitive, specific, reliable, and reproducible method of detecting M. 
bovis compared with both ELISA and traditional biochemical and metabolic tests from culture 
(Ayling et al., 1997; Bashiruddin et al., 2005; Chávez González et al., 1995; Ghadhersohi et al., 
1997; Hotzel et al., 1996; Subramaniam et al., 1998; Tenk et al., 2006; Thomas et al., 2004). 
PCR amplification also allows for the detection of the bacterial DNA in serum or milk, as 
opposed to many of the immunological methods in which serum antibody levels or antigens may 
be detected.The first attempts to detect M. bovis with PCR amplification concentrated on the 
amplification of the 16S rRNA gene, which is universal in bacterial genomes. While this method 
was fast and sensitive there were again some issues with differentiating between M. bovis and M. 
agalactiae. After sequencing the 16S gene of these two bacteria it was found that the genes 
varied by only eight nucleotides and these nucleotides would have to be utilized in the 16S rRNA 
PCR assays for the differentiation between these closely related species. Chávez González et al 
(1995) developed specific primer sets for both M. bovis and M. agalactiae based on the 
nucleotide differences in the 16S rRNA gene that did indeed decrease cross-amplification. Other 
methods implemented to decrease cross-reactivity were the use of multiplex or nested secondary 
PCR amplifications and the addition of restriction enzyme digests post amplification to create 
species specific restriction fragment length polymorphism (RFLP) fingerprint patterns 
(Bashiruddin et al., 2005; Foddai et al., 2005; Hayman and Hirst, 2003; Johansson et al., 1996; 
Tenk et al., 2006). Primers have also been designed for many other conserved M. bovis gene 
targets that are more genetically distinct to improve specificity. The uvrC DNA repair gene, 
membrane protein 81 encoding gene, and oppD oligonulceotide permease encoding gene have all 
20 
 
demonstrated high specificity when used as gene targets in M. bovis amplification. DNA probes 
created from restriction fragments specific to and common in M. bovis have also been utilized to 
produce specific and sensitive PCR primers (Ghadhersohi et al., 1996; Hayman and Hirst, 2003; 
Hotzel et al., 1993; Hotzel et al., 1996; Tenk et al., 2006).  Recently real-time PCR methods have 
been developed to not only detect the presence of M. bovis but also to quantify the abundance of 
M. bovis in samples (Cai et al., 2005; Sachse et al., 2009).  
   A recent study tested seven different methods of M. bovis and M. agalactiae specific 
PCR amplification (Bashiruddin et al., 2005). The study concluded that while some PCR 
methods were more specific than others, all of the systems and gene targets utilized produced 
useable results and were suitable for clinical use (Bashiruddin et al., 2005). In four instances the 
PCR amplification methods were even able to rectify incorrect identifications made by 
biochemical or serological methods (Bashiruddin et al., 2005). Therefore, identification by PCR 
may be an ideal clinical assay due to the increased speed, sensitivity, and specificity over 
serological and culture-based (Hotzel et al., 1996). However, it should be taken into 
consideration that the DNA detected with PCR may not always be from live bacteria; therefore, 
overestimation of active bacteria is possible.   
   It should also be noted that while serological and molecular identification of M. bovis is 
more sensitive, specific and rapid than early biochemical and metabolic testing of cultured 
isolates, bacterial culture is far from obsolete for identification of M. bovis. While rapidity is 
important for clinical testing, scientific studies often greatly benefit from culturing Mycoplasma 
samples prior to species detection. Culture stocks are not only important as a back-up but provide 
high concentrations of bacteria for future testing. For example high quality clean DNA is 
required for most modern strain differentiation techniques; therefore, while species identification 
may be possible from raw samples, culture of the raw samples is often necessary for future 
testing of Mycoplasma species (Butler et al., 2001; Kusiluka et al., 2000; Kusiluka et al., 2001; 
Mannering et al., 2009; McAuliffe et al., 2004; Mettifogo et al 2006; Parham et al., 2006; Tardy, 
2007).   
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2.4.2 Mycoplasma strain differentiation 
   2.4.2.1 Pulse Field Gel Electrophoresis (PFGE)  
   Pulse Field Gel Electrophoresis (PFGE) was first developed by Schwartz and Cantor in 
1984 in response to a need for separating large DNA fragments by size. Distinguishing between 
DNA fragments over 50kb by standard gel electrophoresis is not possible, as these large 
fragments have near indistinguishable rates of motility through an agarose gel matrix (Schwartz 
and Cantor, 1984). Even with very low agarose concentrations and extremely long running times 
resolution between bands of over 750kb via electrophoresis is not possible. Pulse Field Gel 
Electrophoresis (PFGE) is a variation of agarose gel electrophoresis in which the electrical field 
alternates between different angles from the center line. Unlike standard agarose gel 
electrophoresis, PFGE can separate DNA fragments up to 2000kb (Schwartz and Cantor, 1984).   
   The addition of restriction enzyme digests to shorten genomic DNA into more 
manageable fragment lengths prior to pulse field electrophoresis has created a useful tool for 
strain differentiation in epidemiological studies of Mycoplasma species (Kusiluka et al., 2001; 
Mannering et al., 2009; McAuliffe et al., 2004; Mettifogo et al 2006; Parham et al., 2006; Tardy 
et al., 2007). This also allows the estimation of genome size based on compiling various 
fragment sizes (Frey et al., 1992; Hollis et al 1999, Tola et al., 1999). Restriction enzymes with 
very few recognition sites are desirable as they create very few large fragments for PGFE 
analysis and genome size estimation. Therefore, for strain differentiation in Mycoplasmas with 
low G+C content, restriction enzymes with recognition sites containing many G and C residues 
are most popular. Selection of restriction enzymes must be species specific as enzymes tend not 
to cut the genomes of all Mycoplasma species (Frey et al., 1992; Hollis et al 1999, Tola et al., 
1999). With proper enzyme selection PFGE can allow for highly variable banding patterns 
between strains (Kusiluka et al 2001, McAuliffe et al., 2004, Tardy et al., 2007) of Mycoplasma 
spp. with improved discriminatory power over restriction fragment analysis based on the16S 
rRNA gene (Hollis et al., 1999). PFGE also demonstrates good reproducibility between runs, 
especially when enhanced software capable of normalizing runs in different conditions is utilized 
(Duck et al 2003; Kusiluka et al., 2001).  
   PFGE has been successfully utilized in M. bovis associated mastitis studies (Biddle et al., 
2005; Fox 2008). It has been demonstrated with PFGE patterns that while it is possible to isolate 
several M. bovis strains from one herd, or even one animal that many times the same strain will 
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colonize several different locations within the same animal. The observation that strains from the 
mammary tissue identified with PFGE were often the same as those isolated from mammary 
tissue in other quarters of the udder and the blood stream suggests that there may be systemic 
involvement in the spread of M. bovis. It was also observed that while strains isolated from 
mammary tissue also colonized several other body sites, that the heterogeneity between strains 
determined with PFGE was greatest between mammary tissue and respiratory tract. This 
indicates that the strains that cause mastitis may differ from the strains that cause M. bovis 
pneumonia (Biddle et al., 2005).   
   However, there are several drawbacks to PFGE when compared to other methods 
including lower discriminatory power and congruence with random amplified DNA (RAPD) and 
amplified fragment length polymorphism (AFLP) techniques in strain differentiation with some 
Mycoplasma species (Kusiluka et al., 2001; Marois et al 2001a, Marois et al 2001b, McAuliffe et 
al., 2004). In an M. bovis epidemiology study PFGE was compared with RAPD and AFLP, and 
found that PFGE demonstrated the least discriminatory power (McAuliffe et al., 2004). The 
authors elected to use primarily RAPD and AFLP as their strain differentiation tools (McAuliffe 
et al., 2004).  
   Other limitations of PFGE include the lack of universal restriction enzymes able to type 
all strains of Mycoplasma (Frey et al., 1992; Hollis et al 1999, Tola et al., 1999) and the higher 
labour and materials costs compared to other techniques such as RAPD (Mettifogo et al., 2006). 
The use of gel images also makes analysis of fingerprints difficult and advanced statistical 
software such as BioNumerics (Applied Maths, Austin TX) may be required (McAuliffe et al., 
2004). However, despite these limitations of PFGE, in conjunction with low recognition site 
restriction enzyme digests the technique has proved to be a very useful tool in Mycoplasma 
epidemiological studies in several livestock animal hosts (Kusiluka et al., 2001; Mannering et al., 
2009; McAuliffe et al., 2004; Mettifogo et al 2006; Parham et al., 2006; Tardy, 2007). 
       
   2.4.2.2 Random Amplified Polymorphic DNA (RAPD)  
   Random Amplified Polymorphic DNA is another molecular method commonly used in 
Mycoplasma strain differentiation. The technique is a PCR amplification in which an arbitrary 
ten nucleotide primer anneals to several places along both strands of the genome in order to 
produce random fragments of varying lengths that can be visualized with agarose gel 
23 
 
electrophoresis (Geary et al 1994; Williams et al., 1990). The fragment length patterns produced 
vary between strains of bacteria due to polymorphisms in the genomes (Bíró et al., 2006; 
Charleton et al., 1999; Cherry et al., 2006; Cousin-Allery et al., 2000; Feberwee et al., 2005; 
Geary et al., 1994; Mannering et al., 2009; Parham et al., 2006; Stakenborg et al., 2006; Williams 
et al., 1990). The technique is therefore, also utilized as a method of gene mapping (Williams et 
al., 1990).  
    RAPD strain differentiation is popular as there is no need for prior sequence information, 
and the technique requires only a thermocycler and basic knowledge of standard PCR (Williams 
et al., 1990).  Unfortunately, there are also several drawbacks to RAPD strain differentiation. 
The RAPD technique is a relatively simple variation on a standard PCR, in which very low 
annealing temperatures are utilized to allow the random 10mer to anneal to several locations 
along the genome (Williams et al., 1990). However, these low stringency conditions also result 
in very poor reproducibility of the fragment length patterns when analyzed on agarose gel 
electrophoresis, especially with the presence or absence of minor bands (Cherry et al., 2006; 
Cousin-Allery et al., 2000; Feberwee et al., 2005; Mettifogo et al., 2006; Stakenborg 2006). This 
can also lead to difficulty when analyzing results as the presence and absence of minor bands 
cannot be used in establishment of strain specific banding patterns, which in turn can result in 
decreased discriminatory power over other methods (Mettifogo et al., 2006; Stakenborg et al., 
2006). While the equipment required to prepare a RAPD analysis is relatively simple, the 
analysis of gel photos may be very difficult and require advanced statistical software as was 
noted for PFGE in order to evaluate similarity and presence and absence of faint bands between 
isolates (McAuliffe et al., 2004).  
   Many strain dependent banding patterns have been produced from RAPD for several 
pathogenic Mycoplasma spp., and have proven very useful in epidemiologic studies in several 
host species (Bíró et al., 2006; Charleton et al., 1999; Cherry et al., 2006; Cousin-Allery et al., 
2000; Feberwee et al., 2005; Mannering et al., 2009; Parham et al., 2006; Stakenborg et al., 
2006). A study in the United Kingdom on 53 M. bovis isolates was able to group the isolates into 
two major clusters (McAuliffe et al., 2004).  However, this is the only study to date where RAPD 
was utilized in the investigation of M. bovis; therefore, more than two main clusters may be 
detectable if additional strains from other geographical regions or outbreaks were analyzed with 
RAPD.  
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   A variation on RAPD known as arbitrarily-primed PCR (AP-PCR) was used for strain 
differentiation in a M. bovis epidemiology case study in 2001 with greater success (Butler et al., 
2001). The protocol is much the same as the RAPD protocol except instead of one random 
10mer, a primer set originally used to amplify interspersed repetitive DNA elements in 
eubacteria was used. Within three different instances of M. bovis outbreaks seven different AP-
PCR fingerprinting patterns were discovered. In two herd outbreaks the herds were closed and 
only one fingerprinting pattern was recovered from each of these operations throughout the 
outbreaks, signifying that there was most likely only one source of infection and one strain 
responsible for each of the outbreaks. The third outbreak was in a feedlot that acquired cattle 
from many different sources and five different fingerprinting patterns were observed throughout 
the outbreak, signifying several strains and sources of the infection (Butler et al., 2001). This 
study illustrates the potential for random PCR based methods for M. bovis epidemiologic studies, 
as several fingerprinting patterns were possible and the results provided scientific support for the 
epidemiologic information available about possible infection sources in these herds.  
 
2.4.2.3 Amplified Fragment Length Polymorphism (AFLP) 
  Amplified fragment length polymorphism is another fingerprinting method commonly used 
in Mycoplasma epidemiology studies (Kokotovic et al., 1999; Vos et al., 1995). The technique 
requires four main steps. First, genomic DNA must be digested simultaneously or consecutively 
with two restriction enzymes. One of the restriction enzymes should have frequent cut sites the 
other should have relatively few cut sites. In the case of Mycoplasma, the rare cutter often has a 
high G+C content in the recognition site as Mycoplasmas have very low G+C content genomes. 
The use of both a frequent cutting and a rare cutting enzyme allows for smaller fragment sizes to 
be analyzed and allows for management of the number of fragments to be analyzed. The second 
step requires ligation of adapters to the cut sites. Two adapters with unique sequence are used; 
each designed to anneal to the overhang left by either the rare or frequent restriction enzyme. In 
the third step PCR amplification is performed with a primer set specific to the adapters, which 
now flank each restriction fragment. Finally, the resulting amplified fragments can be resolved 
on an acrylamide gel or, if one of the primers is labelled with a fluorescent marker, by automated 
capillary electrophoresis (Vos et al., 1995).  
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   Like other strain differentiation techniques ALFP does not require any previous 
knowledge of the genome sequence. The method also has advantages over other fingerprinting 
methods. In particular, one study tested the reproducibility in Mycoplasma spp. by running all 
samples in duplicate and certain samples in triplicate and found near identical densitometric 
curves produced when analyzed via capillary electrophoresis (Kokotovic et al., 1999). As 
discussed above, the method was also found to have high discriminatory power between different 
strains within a Mycoplasma species (Hong et al., 2005; Kusiluka et al., 2000; McAuliffe et al., 
2004). The development of AFLP databases for comparison may be more feasible than for other 
fingerprinting methods as the use of capillary electrophoresis makes AFLP fingerprints more 
consistent than other methods such as RAPD and PFGE in which agarose gel electrophoresis is 
utilized. The use of capillary electrophoresis in AFLP also simplifies data normalization and 
analysis with clustering software compared to PFGE and RAPD in which gel images must be 
analyzed (Hong et al., 2005; Kusiluka et al., 2000).  
   AFLP has been tested for species differentiation of Mycoplasma spp. and demonstrated 
high heterogeneity between species when suitable restriction enzyme pairs were utilized 
(Kokotovic et al., 1999). In several CPPS studies AFLP has been utilized successfully for strain 
differentiation of M. bovis.  The McAuliffe study comparing PFGE, RAPD and AFLP in the 
differentiation of strains of M. bovis thought to be associated with CPPS in the United Kingdom 
showed that AFLP analysis of the strains resulted in similar clustering as with RAPD (McAuliffe 
et al., 2004). However, one of the main two clusters resulting from both of these methods could 
be sub-grouped with the AFLP data, suggesting possibly higher discriminatory power of AFLP 
over RAPD (McAuliffe et al., 2004).  An early study of 42 M. bovis strains isolated over 17 
years in various geographical regions in Denmark showed 18 different profiles; however, these 
profiles had very high homogeneity (Kusiluka et al., 2000). Clustering was found not to be based 
as much on geographical region but on epidemiological relatedness. Strains from mastitis cases 
were found to be near identical to each other despite length of time between the collection of the 
isolates, suggesting that the genomes of these strains has remained stable over long periods of 
time (Kusiluka et al., 2000).  These studies demonstrate the usefulness of AFLP strain 
differentiation in M. bovis epidemiology research.   
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2.4.2.4 Other genome based strain differentiation techniques 
   The previously described strain differentiation methods have all involved identification of 
genomic diversity. However, none of these methods have attempted to determine the genomic 
region in which these polymorphisms occur. There are however, a few studies in which strain 
differentiation methods have been developed targeting the highly variable regions in the M. bovis 
genome.  Beier et al (1998) investigated the genes encoding the variable surface proteins for 
differences between genetic structure and resultant antigen expression using Southern and 
Western blotting methods, respectively. The study determined that these regions were 
responsible for a high level of divergence between strains and subsequent antigen profiles and 
that these VSP profiles may be useful strain differentiation targets. 
   A more recent study investigated repetitive DNA elements, known as insertion sequences 
that vary in genome position and copy number and code only for proteins involved in their own 
transposition (Miles et al., 2005). As these insertion sequences are involved in chromosomal 
rearrangements they potentially contain the polymorphisms responsible for the genomic variation 
observed between strains with RAPD and AFLP strain differentiation methods. The groups that 
resulted from analysis of the different profiles were comparable to the groups determined via 
RAPD and AFLP results suggesting that the differences in length and copy number of these 
insertion sequences may indeed be responsible for the genome variation detected by RAPD and 
AFLP.  
   Variable number tandem repeats (VNTR) have also been studied as possible genome 
elements responsible for genomic variation between M. bovis strains in one study (McAuliffe et 
al., 2008). VNTRs are DNA elements that are repetitive and can vary in copy number. Databases 
for VNTR profiles exist for many bacteria; therefore, VNTR profiling is being used for strain 
typing in several species. This study utilized VNTR profiling in M. bovis found that like AFLP 
and RAPD, VNTR analysis was able to differentiate strains to a higher degree than PFGE. 
   Methods of strain differentiation that take into account the regions responsible for 
genomic variation between strains and possible differences in phenotypes may be an important 
step in understanding the variable pathogenicity observed in M. bovis epidemiology studies.  
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 2.5 Conclusion  
  The literature supports a strong association between M. bovis and CPPS in feedlot cattle 
with specific pathology of the disease condition well defined and differentiated from other 
feedlot pneumonias. It is difficult to generalize on the prevalence of this pathogen in feedlots as 
differences in sample type, geography and identification methodology make comparisons of 
prevalence studies extremely difficult.  
  In addition to being associated with CPPS, M. bovis is also known to be a causative agent 
of many other bovine diseases and can be isolated from seemingly healthy animals. However, the 
mechanisms regulating the type of disease or in some cases the lack of disease induced after M. 
bovis colonization is unknown. The host response to infection with M. bovis may impact the 
disease outcome. In CPPS afflicted animals a Th2 skewed immune response can be observed, 
that may protect the host from severe immune induced lung damage associated with either Th1 
or Th2 polarized response. However, this skewed response may also factor into the chronicity of 
CPPS. To date, there are no comparative studies examining the host immune response between 
different disease outcomes; therefore, host response as a factor in M. bovis associated diseases is 
not well defined.  
  Variability in adherence and other pathogenicity factors has been noted between different 
field strains of M. bovis indicating that different strains may be present within the species with 
different levels of virulence and tissue specificity. This is another plausible explanation for the 
variable disease states. Strain differentiation techniques based on identification of 
polymorphisms throughout the whole genome have been developed and utilized in strain 
differentiation studies. However, there is still relatively little research regarding how the different 
strains identified with these methods relate to disease state. Identifying these strain differences is 
the first step in understanding the differences between disease states in cattle upon colonization 
with M. bovis. The identification of virulent strains may also have practical benefits for 
detection, treatment and vaccination strategies.  
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3.0 A SURVEY OF MYCOPLASMA BOVIS STRAINS IN WESTERN CANADIAN FEEDLOT 
CATTLE  
 3.1 Introduction 
   Mycoplasma bovis is a bacterial pathogen associated with several different conditions in 
cattle including, keratoconjunctivits, otitis media, mastitis, respiratory disease and arthritis 
(Alberti et al., 2006; Gagea et al., 2006; Maeda et al., 2003). A lack of cell wall makes M. bovis 
inherently resistant to the β-Lactam family of antibiotics and the bacteria is gaining resistance to 
most of the other groups of antibiotics commonly used in cattle (Francoz et al., 2005; ter Laak et 
al., 1993). The surface proteins expressed by M. bovis are variable making an antigenic target for 
vaccine production difficult; therefore, no efficacious vaccine is available for most M. bovis 
associated diseases (Francoz et al., 2005; ter Laak et al., 1993). Chronic Pneumonia and 
Polyarthritis syndrome is an M. bovis associated disease in feedlot cattle that is characterized by 
persistent respiratory disease despite antibiotic treatment and subsequent arthritis in one or 
several joints (Behrens et al., 1996, Le Grand et al., 1996, Lysnyansky et al., 1996; Lysnyansky 
et al., 1999; Poumarat et al., 1998; Sachse et al., 2009). The difficulty in treating and preventing 
this condition make it of great concern to beef producers as CPPS poses significant welfare and 
economic concerns in the feedlot (Nicholas and Ayling, 2003).  
   The prevalence of M. bovis has been studied widely in North America, Australia and 
Europe (Arcangioli et al., 2008; Assié et al., 2009; Ayling et al., 2004; Bashiruddin et al., 2001; 
Blackburn et al., 2007; Ghadhersohi et al., 1999; Gagea et al., 2006, Le Grand et al., 2002; 
Wiggins et al., 2007); however, there are currently no M. bovis prevalence studies conducted in 
western Canada. The results of previously reported prevalence studies vary widely and while this 
may be due to the different geographical regions there are also many discrepancies in the 
sampling period, sampling method and identification method among these studies. Several 
studies have observed poor agreement between M. bovis isolation from nasal swabs (NS) and 
bronchoalveolar lavage (BAL), suggesting that sampling method may be important for consistent 
results and that NS may not be good indicators of M. bovis status in the lower respiratory tract 
(Allen et al., 1991; 1992; Catry, 2008; Thomas et al., 2002). Also the sampling period appears to 
affect the prevalence results as several studies have observed an increase in M. bovis isolation 
with an increase in the days the animal has been in the feedlot (Allen et al., 1992; Rosendal and 
Martin et al., 1986). The variation in results due to sampling differences and methodology in 
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studies from other regions make it difficult to make any inferences about the Mycoplasma 
prevalence in western Canada.  
   While M. bovis has been shown to be highly associated with CPPS and cause CPPS upon 
inoculation in both gnotobiotic and conventional calves, previous prevalence studies also often 
observed M. bovis colonizing the respiratory tracts of seemingly healthy cattle (Allen et al., 
1991; 1992; Hirose et al., 2003; Rosendal and Martin, 1986; Sachse et al., 2009; ter Laak et al., 
1992b; Thomas et al., 2002; Wiggins et al., 2007). This would suggest that there is variability of 
pathogenicity within the species. Molecular strain differentiation has recently been utilized to try 
and identify different strains in M. bovis epidemiology studies. Random Amplified Polymorphic 
DNA (RAPD) is a strain differentiation method that utilizes a random nucleotide primer in 
standard PCR reactions in order to reveal polymorphisms between the genomes of strains (Butler 
et al., 2002; McAuliffe et al., 2004). The method has been utilized in M. bovis epidemiology 
studies and has demonstrated high discriminatory power when compared to other methods. A 
study was conducted to compare strain differentiation methods and found that RAPD was able to 
separate 56 M. bovis isolates collected over a 6 year period in the United Kingdom into two 
genetically distinct clusters (McAuliffe et al., 2004). The same study also compared a strain 
differentiation method known as Amplified Fragment Length Polymorphism (AFLP) that utilizes 
a double digest with restriction enzymes followed by a PCR of the resultant fragments in order to 
identify genomic polymorphisms within a species. The study found that this method was 
consistent with RAPD and produced the same genetically distinct clusters; however, AFLP was 
able to identify two sub-groups within one of these clusters; therefore, may have higher 
discriminatory power than RAPD. While these strain differentiation methods do appear to be 
suitable for M. bovis and have provided useful information regarding M. bovis epidemiology, to 
date there are no significant relationship between strains identified with these methods and 
pathogenicity or disease outcome.  
   The aim of this study was to determine the prevalence of M. bovis in healthy University 
of Saskatchewan feedlot, commercial feedlot cattle that developed respiratory disease within 3 
months of arrival at the feedlot, and in CPPS mortalities from several western Canadian feedlots 
upon necropsy in order to determine any differences in prevalence due to sampling method, 
sampling period, or disease status. In addition, AFLP was selected to genotypically differentiate 
M. bovis isolates obtained following feedlot entry and to compare these with M. bovis isolates 
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recovered from western Canadian feedlot that died or were euthanized following CPPS-like 
clinical presentations.  
  
 3.2 Materials and methods  
  3.2.1 Sample collection  
   3.2.1.1 Healthy University of Saskatchewan feedlot cattle  
   Thirty-six clinically healthy steers weighing between 219 – 333 kg and housed at the 
University of Saskatchewan feedlot were sampled at 14 and 90 days on feed (DOF) in the fall of 
2008 and winter of 2009. Nasal swabs (NS) were taken with a double guarded equine uterine 
swab (Reproduction Resources, Walworth WI) inserted in the right nasal passage and were 
stored in Ames media at -80°C until culture (Mai, Ames Media, Product Number 49203, Spring 
Valley WI). Bronchoalveolar lavages (BAL) were collected immediately after NS by advancing 
a 90 cm optical endoscope (Olympus; Markham, Ontario, Canada) through the left nostril to the 
accessory lung lobe. Sterile plastic tubing was then advanced through the channel of the 
endoscope to 10 cm past the end of the scope.  Approximately 120 mL of sterile buffered saline 
was flushed into the bronchus using a sterile 60 cc syringe. Within 10 seconds the saline was 
aspirated back into the syringe. In some instances, the saline gravitated into the lung field and no 
aspirate was collected, in which case the lung was lavaged with a 2nd 60 mL of fluid. Typically 
1-5 mL was aspirated and a small aliquot (0.5 – 1.0 mL) was placed in 1.2 mL cryogenic vial 
(Nalgene) to be stored at -80 °C until culture.  The endoscope was disinfected with alcohol 
between animals to prevent transfer of bacteria.    
    
   3.2.1.2 Symptomatic commercial feedlot cattle 
   Nasal swabs were collected on two occasions from cattle in a commercial feedlot (Pound-
Maker Agventures Ltd., Lanigan, Saskatchewan) in the fall of 2007 using methods described in 
section 3.2.1.1. Swabs were collected from approximately 650 feedlot calves between 180 and 
300 kg upon feedlot entry and again between 1 week and 3 months of arrival for 56 calves (35 
from pen A and 21 from pen B) identified and treated for respiratory symptoms. Nasal swabs 
collected by feedlot staff at time of treatment were stored at -20 °C until transfer to the 
University of Saskatchewan where they were stored at -80 °C until cultures. Nasal swabs 
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collected from cattle sorted for treatment and from the same cattle at the time of feedlot entry 
were cultured for M. bovis identification and strain differentiation.  
     
   3.2.1.3 Necropsy samples  
   Sample collection kits were sent to western Canadian veterinary clinics with instructions 
to collect samples of CPPS lesions from lung and joint of carcasses only if both randomly 
distributed raised caseous micro-abscesses and evidence of septic arthritis indicative of M. bovis 
associated CPPS were evident upon necropsy. Four different veterinary clinics participated and a 
total of 62 cattle carcasses from 14 different feedlots in western Canada were included.  Swabs 
were collected through sterile openings in arthritic stifle or hock joints using small swabs (Mai, 
Spring Valley, WI).  Lung tissue samples of 3 cm by 3 cm with lesions were collected from the 
diaphragmatic lung lobes of the carcasses. All samples were stored at -20 °C until they could be 
transferred to the laboratory within two months from collection, where they could be stored at     
-80 °C until culture within the next six months. Due to technical difficulties, species 
identification was only conducted for 108 isolates (61 lung and 47 joint) from 29 animals and 
strain differentiation was only possible for 58 isolates (35 lung and 23 joint) from 19 animals 
originating from ten different feedlots.  
 
  3.2.2 Selective culture and isolation of presumptive Mycoplasma species 
   Within 6 months of collection frozen samples were thawed and streaked onto Hayflick’s 
agar and incubated at 37 ºC in 5% CO2 for 48 hrs.  Preliminary data showed that sample storage 
in Ames media at -80 ºC up to 12 months did not affect the number of colonies enumerated on 
Hayflick’s agar. Following incubation, four presumptive Mycoplasma spp. colonies were 
selected and sub-cultured onto Hayflick’s agar under the same conditions for an additional 48 hrs 
at 37 ºC in 5% CO2.  These subcultured colonies were then inoculated into 4-10 mL of 
Hayflick’s broth under the same temperature and atmospheric conditions for 3-7days.  Stocks of 
0.50 - 0.75 ml Hayflick’s broth and 0.50 – 0.75 mL litmus milk were saved in 1.5 ml Eppendorf 
tubes at -80 ºC.   
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  3.2.3 Species identification 
   One to four colonies for each sample were speciated. Fresh broth cultures (4-10 mL) 
were centrifuged at 3000 rpm for 1 hr and the supernatant removed. Genomic DNA was 
extracted from the resultant bacterial pellet using PurelinkTM Genomic DNA Kit (Invitrogen, 
Carlsbad, CA) according to the instruction manual for gram negative bacterial cell lysates. The 
extracted DNA was quantified and examined for purity using UV absorbance (NanoDrop® ND-
1000 spectrophotometer; NanoDrop Technologies, Inc., Wilmington, USA) and stored at -80 ºC 
until use.  
   Polymerase Chain Reaction (PCR) was employed to amplify the 16s rRNA gene for 
nucleotide sequencing. The PCR reaction mixture included 1x PCR Buffer (Invitrogen, 
Burlington, ON), 1.5 mM MgCl2, 0.2 mM dNTPs, 3 mM BSA, 0.5 mM universal 16S rRNA 
gene forward primer (5’-GAGTTTGATCCTGGCTCAG-3’), 0.5 mM universal 16S rRNA gene 
reverse primer (5’-GWATTACCGCGGCKGCTG-3’), at least 10 ng of PurelinkTM extracted 
genomic DNA, 0.5 µL Taq polymerase (Invitrogen, Burlington, ON) and ddH20 to bring the 
reaction mixture volume to 50 µL. A hot start at 95 °C for 10 min in an Amplitron II 
thermocycler (Thermolyne, Barnstead International, Dubuque, Iowa) was utilized before Taq 
was added to the reaction mixture. PCR amplification continued for 40 cycles using a denaturing 
phase of 95 ºC for 30 sec, an annealing phase at 50 °C for 30 sec, and an extension phase at 72 
ºC for 30 sec. 
   Successful PCR amplification was confirmed by electrophoresis of 50 µL of the 
completed PCR reaction with 10 µL of a 0.5% bromophenol loading buffer using a 1.5% agarose 
gel containing 0.5 µg/mL ethidium bromide at 100 V for 1.5 hrs (BioRad Model 1000/500 Power 
Supply, BioRad, Hercules, California). PCR products of 660bp were extracted from the agarose 
gel with the Qiaex II Gel Extraction Kit as outlined in the DNA Extraction from Agarose Gels 
section of the Qiaex II handbook (Qiagen, Mississauga, Ontario). DNA in gel-purified PCR 
products was quantified with the NanoDrop® ND-1000 spectrophotometer and submitted to the 
National Research Council, Plant Biotechnology Institute (Saskatoon, SK) for DNA sequencing 
with the 16s universal primers previously described.  
   Raw nucleotide sequence data was processed with the PREGAP v1.5 and GAP4 v4.10 
programs of the Staden package (Dear and Staden 1991) in order to align forward and reverse 
sequences, confirm sequence quality and delete primer sequences. Trimmed, quality sequences 
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were uploaded to the 16S Ribosomal Database Project II (Cole et al., 2207; Cole et al., 2009) 
website and the Sequence Match tool used to identify the nearest bacterial species match.  
Phylogenetic analysis and tree construction of sequences was performed using ARB 
phylogenetic software (Ludwig et al., 2004).  
   
  3.2.4 RAPD strain differentiation 
   A 50 µL RAPD reaction was prepared containing 1x PCR Buffer (Invitrogen, Burlington, 
ON), 1.5 mM MgCl2, 0.2 mM dNTPs, 0.1% Triton X-100, 1 mM primer Hum4 5’-
ACGGTACAT-3’ (Hotzel et al., 1998), at least 50 ng of sample DNA, 5 uL Taq polymerase 
(Invitrogen, Burlington, ON)   and UV ddH20 to bring the reaction mixture volume to 50 µL. 
The RAPD reaction mixtures were subjected to 95 ºC for 3 min and then 40 cycles of 95 ºC for 
30 sec, 37 °C for 30 sec, and 72 ºC for 30 sec in the Amplitron II thermocycler (Thermolyne, 
Barnstead International, Dubuque, Iowa). RAPD amplification products were then assessed with 
electrophoresis on a 2% agarose gel containing 0.5 µg/mL ethidium bromide. The voltage used 
was initially 140 V for 5 min followed by 90 V for 1.5 hrs (BioRad Model 1000/500 Power 
Supply, BioRad, Hercules, California). Gels were visualized under UV illumination.  
 
  3.2.5 AFLP strain differentiation  
   For isolates confirmed by 16s rRNA gene sequencing as M. bovis, extracted genomic 
DNA was amplified with the illustra GenomiPhi HY DNA Amplification Kit as described in the 
manual (GE Healthcare, Buckinghamshire, UK). GenomiPhi amplification products were 
quantified with Picogreen® as described in the manual (Picogreen® dsDNA Quantitation Kit, 
Molecular Probes Inc, Eugene, Oregon). Approximately 150-500 ng of DNA was digested with 
10 U of MfeI and 10U of BglII restriction enzymes (New England Biolabs, Beverly, Mass.) in a 
buffer previously described by Kokotovic et al (1999) at 37 ºC for 6 hrs. Double stranded 
adapters were prepared. A ligation reaction consisting of 5 µL of restriction enzyme digest, 10 
pmol of a double stranded BglII adapter, 100 pmol of a double stranded MfeI adapter, 1 U of T4 
DNA ligase (New England Biolabs, Beverly, Mass.) and the previously described buffer was 
incubated at room temperature for 16-20 hrs.   
   PCR amplification from 1 uL of a 1:10 diluted ligation reaction product was performed. 
PCR reactions consisted of a 1x PCR Buffer (Invitrogen, Burlington, ON),  2.5mM MgCl2, 0.2 
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mM of each of the four dNTPs, 65 ng of MFE1-0 primer, 65ng of BGL2F-0 primer 0.3 uL Taq 
polymerase (Invitrogen, Burlington, ON) and UV ddH20 to bring the reaction mixture volume to 
50 µL. Amplification was run in a Biorad C1000TM Thermal Cycler (Biorad, Mississagua, 
Ont.). An initial 3 min denaturation at 95 ºC was performed, followed by 40 cycles of 
denaturation at 95 ºC for 60 sec, annealing at 54 ºC for 60 sec and elongation at 72 ºC for 90 sec. 
Amplification completed with a final elongation step of 72 ºC for 10 min.   
   Amplification fragments were analyzed on an ABI 3130xl Genetic analyzer (Applied 
Biosystems, Foster City, CA). Mixtures of 1µl of 1:50 (v/v) dilution in ddH2O of amplification 
product, 1 µL Genescan 600 Liz internal size standard (Applied Biosystems, Foster City, CA) 
and 8µl formamide were denatured at 95 ºC for 5 min and placed on ice for 2 min before 
detection.  
   Densitometric curves from the ABI 3130x Genetic Analyzer were uploaded into 
Genemapper v3.7 and 5 bin analysis for AFLP, in which the software searches for significant 
peaks every 5 nucleotides, was performed. Compared across all samples, restriction fragments 
within a range of 5 bp were considered a single peak and peak areas combined under a single 
size (bp) designation. Resulting peak area profiles were imported into Bionumerics v5.1 
(Applied Maths, Austin, TX). Clusters were made based on Dice similarity coefficient similarity 
using the unweighted pair group method with arithmetic mean (UPGMA) algorithm with 
optimization and position tolerance settings at 0% and 1% respectively. A reproducibility trial 
was conducted in which nine samples, at least two from each AFLP plate analyzed, were run and 
analyzed in duplicate with the identical AFLP protocol, supplies, equipment and software. 
 
  3.2.6 Statistical analysis  
   Statistics were analyzed with SPSS v18.0 software. For comparison of Mycoplasma spp. 
prevalence between different sampling times and methods McNemar’s Symmetry test was used. 
The Kappa test was used for comparing the agreement of M. bovis status of animals at various 
time points and sampling procedures. Fisher’s exact two-tailed test was also used to compare the 
the prevalence of each strain, isolated at various sampling times and body sites as well as with 
different sampling methods.  
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 3.3 Results 
  3.3.1 Mycoplasma species prevalence 
     3.3.1.1 Healthy University of Saskatchewan feedlot cattle  
 Mycoplasma bovirhinis was the most common Mycoplasma spp. cultured from NS and 
BAL samples taken from healthy University of Saskatchewan feedlot cattle (Table 3.1), followed 
by M. bovis. An increase in M. bovis positive animals was observed at 90 days on feed compared 
to 14 days on feed in NS (P < 0.01). Fewer animals were positive for M. bovis in BAL compared 
to NS, however, the number of M. bovis animals also tended to increase (P =0.07) in BAL 
between 14 and 90 days on feed (Table 3.1). No difference was observed for animals positive for 
M. bovirhinis (NS, P = 0.50; BAL, P = 0.24) or other species (NS, P = 0.38; BAL, P = 1.00) 
between 14 and 90 days on feed in either NS or BAL samplings (Table 3.1). Only two 
Mycoplasmas spp., other than M. bovis and M. bovirhinis, were cultured from University of 
Saskatchewan feedlot cattle (Table 3.1), namely M. alkalescens and M. bovoculi. While no 
difference was observed between the number of animals in which no Mycoplasma spp. could be 
cultured from NS samples at 14 and 90 days on feed (P = 0.63), a  decrease in Mycoplasma 
negative animals was observed between 14 and 90 days on feed in BAL samples (P = 0.03; 
Table 3.1).  Multiple Mycoplasma spp. were cultured from between 6-11% of healthy University 
of Saskatchewan cattle tested and there was no difference between the number of animals in 
which multiple species could be cultured at 14 versus 90 days on feed in the either the NS (P = 
1.00 ) or BAL (P = 1.00) samples (Table 3.1).  
 There was poor agreement (K = 0.05, P = 0.62) between the M. bovis status of an animal 
at 14 DOF compared to 90 DOF (Table 3.3). Fair agreement (K = 0.25, P = 0.05) was noted 
between the M. bovis status as determined by NS compared to BAL (Table 3.4). Furthermore, 
while not statistically significant, the prevalence of M. bovis was also higher in NS compared to 
BAL at both 14 (P = 0.38) and 90 (P = 0.06) DOF.  
 
   3.3.1.2 Symptomatic commercial feedlot cattle  
Mycoplasma bovis and M. bovirhinis were also the most prevalent Mycoplasma spp. 
cultured from nasal swabs taken from cattle that developed respiratory disease symptoms 
between one week and three months after arriving at a commercial feedlot in Saskatchewan 
(Table 3.2). However, in these cattle, M. bovis was the most common. The number of animals 
36 
 
positive for M. bovis was higher upon treatment for respiratory disease than upon arrival (P = 
0.01; Table 3.2). However, there was no difference between the numbers of animals that had 
positive cultures for M. bovirhinis when sampled at arrival compared to time of treatment (P = 
0.19; Table 3.2).  In the commercial feedlot, four other species of Mycoplasma were cultured 
including in order of prevalence M. ovipneumoniae, M. lagogenitalium, M. alkalescens, and M. 
cynos. While not significant the number of animals positive for these other species tended to be 
greater at the time of treatment than upon arrival (P = 0.08; Table 3.2). The number of animals in 
which multiple Mycoplasma spp. could be cultured also increased from the time of arrival to the 
time of treatment; however, this was not different (P = 0.08; Table 3.2). The number of animals 
in which no Mycoplasma spp. was cultured from nasal swabs was greater upon arrival than at 
time of treatment (P = 0.02; Table 3.2).   
There was poor agreement (K = 0.04, P = 0.78) between the M. bovis status of a 
commercial feedlot animal on arrival at the feedlot and the status one week to three months later 
upon treatment for respiratory disease symptoms (Table 3.5).  Consequently, for both feedlots, 
animals that were positive for M. bovis at entry occasionally became negative, and consistent 
with increased prevalence, many M. bovis negative animals at entry became positive.  
 
   3.3.1.3 Necropsied cattle  
Presumptive Mycoplasma colonies were observed on culture of swabs on Mycoplasma 
spp. specific agar for 93% of the 61 lung samples and 77% of the 47 joint samples.  However, 
due to technical difficulties only subcultured colonies from 29 animals were available for 
speciation by sequencing of 16S rRNA gene. Twenty five of the 29 animals were identified as M. 
bovis positive. Of the remaining, three animals were identified as having only M. alkalescens and 
one animal identified as Paenibacillus chibensis. 
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3.3.2 Establishment of Mycoplasma bovis strain differentation methodology 
   The RAPD strain methodology adapted from the McAuliffe et al (2004) M. bovis strain 
differentiation study failed to produce reliable and reproducible results. Success of the RAPD 
protocol, as determined by presence of bands when visualized with ethidium bromid under UV 
light, between samples run in duplicate with identical protocol, supplies and equipment was 
inconsistent (data not shown). The number and intensity of bands between duplicate runs was 
also inconsistent (data not shown); therefore, RAPD was determined to be unsuitable for this 
study.  
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Table 3.1 Classification of University of Saskatchewan feedlot cattle (percent of total in 
brackets) according to the bacterial species assignment of presumptive Mycoplasma isolates 
cultured from nasal swabs (NS) and bronchoalveolar lavage (BAL) samples taken from feedlot 
steers at 14 and 90 days on feeda.  
Sample 
Type 
Days 
on 
Feed 
umber 
of 
Animals
b 
M. 
bovis
c 
M. 
bovirhinis 
Other 
Species 
Multiple 
Species
 
o 
Mycoplasma 
Growth 
NS 14 36 4 (11) 19 (53) 4 (11) 4 (11) 13 (36) 
NS 90 36 14 (39) 15 (42) 1 (3) 4 (11) 10 (28) 
P valued 
 
 <0.01 0.50 0.38 1.00 0.63 
BAL 14 36 1 (3) 11 (31) 1 (3) 2 (6) 25 (69) 
BAL 90 36 7 (19) 17 (47) 0 (0) 2 (6) 14 (39) 
P valued  
 
0.07 0.24 1.00 1.00 0.03 
a Data previously reported as part of Dr. Nathan Erickson’s M.Vet.Sc. at the Western College of 
Veterinary Medicine, University of Saskatchewan in 2009.  
b Individual animals may be represented in more than one Mycoplasma group classification 
(column).   
c Bacterial species assignment based on partial 16S rRNA gene sequence analysis 
d P values determined with McNemar’s test.  
 
Table 3.2 Classification of cattle from a commercial feedlot in Saskatchewan Canada (percent of 
total in brackets) according to the bacterial species assignment of presumptive Mycoplasma 
isolates cultured from nasal swab samples taken from feedlot steers on arrival at the feedlot and 
at treatment for respiratory disease 1-3 weeks later.  
Sample 
Time 
umber  
of 
Animals
a 
M. bovis 
M. 
bovirhinis 
Other 
Species 
Multiple 
Species
b 
o 
Mycoplasma 
Growth 
On arrival 56 24 (41) 18 (32) 1 (2) 4 (7) 17 (30) 
At treatment 56 38 (68) 11 (19) 14 (25) 12 (21) 5 (9) 
P  valuec   0.01 0.19 <0.01 0.08 0.02 
a Bacterial species assignment based on partial 16S rRNA gene sequence analysis 
b Bacterial species assignment based on partial 16S rRNA gene sequence analysis Individual 
animals may be represented in more than one Mycoplasma group classification (column)   
c P value determined using McNemar’s test. 
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Table 3.3 Agreement between Mycoplasma bovis status (+ or -) of individual animals at 14 DOF 
compared to 90 DOF in the University of Saskatchewan feedlota.  
 umber of 
Animals 
M. bovis + 90DOF
b 
# of animals (%) 
M. bovis – 90DOF 
# of animals (%) 
M. bovis + 14DOF
b 3 2 (67) 1 (33) 
M. bovis – 14DOF 29 15 (52) 14 (48) 
a The M. bovis status of an animal at 14 DOF is in poor agreement with the status at 90 DOF (K = 
0.05, P = 0.62).  
b Defined as animals M. bovis positive for either a BAL or NS sample 
 
 
 
 
 
 
 
Table 3.4 Agreement between Mycoplasma bovis status (+ or -) of individual asymptomatic 
animals with NS compared to BAL at the University of Saskatchewan feedlota. 
 
Sampling 
Occassion
b BAL +
 
BAL –  
S + 17 5 (29) 12 (71) 
S - 36 3 (8) 33 (92) 
a 
M. bovis status determined in NS is in fair agreement with the status as determined by BAL  
(K = 0.25, P = 0.05).  
b Represents the number of sampling occasions for which BAL and NS were available for a 
single animal.  
 
 
 
 
 
 
 
Table 3.5 Agreement between Mycoplasma bovis status (+ or -) of individual animals OA 
compared to AT in a commercial feedlot (Pound-Maker Agventures Ltd., Lanigan, 
Saskatchewan)a.  
 
umber of 
Animals 
M. bovis + AT
 
# of animals (%)
 
M. bovis – AT 
# of animals (%) 
M. bovis + OA 21 17 (81) 4 (19) 
M. bovis – OA 13 10 (77) 3 (23) 
a 
M. bovis status on arrival at the feedlot is in poor agreement with the status one week to three 
months later (K = 0.04, P = 0.78).  
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3.3.3 AFLP Strain differentiation of Mycoplasma bovis isolates 
   The AFLP protocol resulted in much higher reliability and reproducibility of banding 
patterns compared to RAPD. Fingerprints consisting of between 20-60 fragments were produced 
for single samples with the AFLP protocol. Only minor changes in densitometric curve and band 
assignment was observed on analysis of nine duplicate samples. Similarity score, based on the 
dice coefficient, between duplicate samples was consistently above 92% (Figure 3.1).   
   AFLP strain differentiation and subsequent cluster analysis of M. bovis strains isolated 
from the 19 animals at necropsy revealed three main clusters, labelled A, B and C (Figure 3.2). 
Isolates within each cluster show a similarity score of greater than 75% based on the dice 
coefficient (Figure 3.2). Strain A was isolated from both the lung and joint samples of the 
majority of animals (Table 3.6); however, isolation of multiple strains was not uncommon from 
the same lung (38% of tissues) or joint sample (29% of tissues; Table 3.6).  Samples for both 
joint and lung were available for only seven animals; therefore, this group is too small for 
statistical comparison. However, five of these animals were colonized by multiple strains and for 
three of these a unique strain was isolated from each tissue. 
Only presumptive Mycoplasma isolates that were identified as M. bovis were subject to 
strain differentiation analysis using AFLP. Of the 67 M. bovis positive isolates from the 
University of Saskatchewan feedlot cattle, 47 could be differentiated with AFLP. These isolates 
represented 17 of the 21 animals that were classified as M. bovis positive in the study. Strain 
differentiation was possible on 140 of the 190 M. bovis positive isolates from the commercial 
feedlot representing 41 of 45 animals positive for M. bovis at either sampling point. The missing 
M. bovis positive isolates were excluded from strain differentiation analysis due to either failed 
culture from frozen stocks, insufficient DNA recovery or failure of AFLP to produce a 
fingerprint for one of the sampling periods.  
   The AFLP fingerprints from the commercial feedlot group isolates clustered almost 
entirely (99%) with necropsy group A isolates (Figure 3.3), with the exception of one isolate that 
clustered with necropsy group B (Figure 3.3). Of the isolates cultured from NS and BAL samples 
of University of Saskatchewan feedlot cattle 68% clustered with strain group B of the necropsy 
isolates (Figure 3.4), with 32% clustering within necropsy strain group A (Figure 3.4). None of 
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the isolates from either the University of Saskatchewan (Figure 3.4) or commercial feedlot 
animals (Figure 3.3), respectively, clustered with the necropsy group C.  
   There was no significant difference in the prevalence of each cluster isolated in joint and 
lung tissue of cattle at necropsy (Table 3.6). Similarly, no difference in the prevalence of any 
cluster was observed comparing 14 and 90 days on feed (Table 3.7) or comparing feedlot entry 
with day of treatment (Table 3.8).  Finally, no significant difference between the prevalence of 
each cluster isolated from BAL compared to NS was observed (Table 3.9).  
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Figure 3.1 Dendogram showing the relationship between AFLP banding patterns for duplicate 
Mycoplasma bovis strains isolated from feedlot cattle. Amplified fragments were identified from 
the densitometric curves with Genemaper v3.7 software. The dendogram was then produced 
using UPGMA clustering of Dice similarity coefficient SD (%) values (Bionumerics v.5.1). 
Alphanumeric characters at right include a unique numerical identifier (1-9) for each sample; 
duplicates are labelled a and b. 
  
Figure 3.2 A dendogram showing relationship among
bovis isolates cultured from lung or joint of
Pneumonia and Polyarthritis Syndrome
C. The dendogram was produced based on 
%) values (Bionumerics v.5.1). Unique identifiers for each isolate are given at right where PM 
designates post-mortem and remaining characters according to 
animal designation (single digit numeral)
lung (L) or joint (J) sample site and column
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 AFLP banding patterns 
 cattle with clinical pathology indicative of Chronic 
. Three genetically distinct clusters are labelled A, B 
UPGMA clustering of Dice similarity coefficient 
a scheme where column 
, b a feedlot designation (upper case letter)
 d a colony number. 
 
for Mycoplasma 
and 
(SD 
a is an 
, c indicates 
  
Figure 3.3 A dendogram showing relationship among
bovis isolates cultured from nasal swab
Saskatchewan and from joint and lung tissue of 
Chronic Pneumonia and Polyarthritis Syndrome. 
the clustering of necropsy samples shown in Figure 3.2. 
UPGMA clustering of Dice similarity coefficient 
represents necropsy strains, yellow represents isolates from asymptomatic calves on arrival at 
feedlot and blue represents isolates taken from
treatment for symptoms of respiratory disease.
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s collected from cattle at a commercial feedlot in 
cattle with clinical pathology indicative of 
Three clusters are labelled A, B and C based 
The dendogram was produced based on 
(SD %) values (Bionumerics v.5.1)
 these cattle one week to three months 
 
 
 Mycoplasma 
on 
. Green 
later upon 
  
Figure 3.4 A dendogram showing relationsh
bovis strains isolated from nasal swab (NS) or 
from  asymptomatic University of Saskatchewan feedlot
and C based on the clustering of 
produced based on UPGMA clustering 
v.5.1). Green represents necropsy
NS isolates. 
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 strains, blue represents BAL isolates, and yellow represents 
 
 Mycoplasma 
samples taken 
 (Bionumerics 
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Table 3.6 Number (and percent) of cattle in the CPPS clinical presentation necropsy group 
colonized in lung or joint with Mycoplasma bovis isolates that cluster in group A, B, and C as 
shown in Figure 3.2.  
Sample Type 
umber of 
Animals
a Cluster A  Cluster B  Cluster C  
Multiple 
Clusters 
 
Lung
b
  17 12 (71) 5 (29) 5 (29) 5 (29) 
Joint
b 8 8 (100) 1(13) 2 (25) 3 (38) 
a Individual animals may be represented in more than one cluster classification (column).   
Cattle included in ‘Multiple Strains’ column not also included in ‘Strain A’, ‘Strain B’ and 
‘Strain C’ columns.  
b No significant difference between the prevalence of strains present in lung and joint samples 
(Fisher’s exact test, two sided: P = 0.54) 
 
 
Table 3.7 Number (and percent) of cattle from a commercial feedlot in Saskatchewan on arrival 
at the feedlot and one week to three months post arrival at treatment for respiratory disease that 
are colonized with Mycoplasma bovis strains clustering in necropsy group A, B, and C as shown 
in Figure 3.2. 
Sample Time 
umber of 
Animals
a Cluster A Cluster B  Cluster C 
Multiple 
Clusters 
On Arrival
b 24 24 (100) 0 (0) 0 (0) 0 (0) 
At Treatment
b 38 38 (100) 1 (3) 0 (0) 1 (3) 
a Individual animals may be represented in more than one cluster classification (column).   
bNo significant difference in the prevalence of strains isolated from animals on arrival and at 
treatment for respiratory disease (Fisher’s exact test, two sided: P = 0.42). 
 
 
 
Table 3.8 Number (and percent) of cattle the University of Saskatchewan feedlot at 14 and 90 
days on feed (DOF) that are colonized with Mycoplasma bovis strains clustering in necropsy 
group A, B, and C as shown in Figure 3.2. 
Sample 
Time 
umber of 
Animals
a
 
Cluster A Cluster B Cluster C 
Multiple 
Clusters 
14DOF
b 5 2 (40) 3 (60) 0 (0) 0 (0) 
90DOF
b 12 6 (50) 11 (92) 0 (0) 5 (42) 
a Individual animals may be represented in more than one cluster classification (column).   
b No significant difference in the prevalence of strains isolated from animals at 14 and 90 days on 
feed (Fisher’s exact test, two sided: P = 0.85) 
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Table 3.9 Number (and percent) of cattle the University of Saskatchewan feedlot in which nasal 
swabs (NS) or bronchoalveolar lavage fluid (BAL) were colonized with Mycoplasma bovis 
strains clustering in necropsy group A, B, and C as shown in Figure 3.2. 
Sample 
Type  
umber of 
Animals
a Cluster A Cluster B Cluster C 
Multiple 
Clusters 
S
 b 13 5 (38) 11 (85) 0 (0) 3 (23) 
BAL
b 7 3 (43) 6 (86) 0 (0) 2 (29) 
a Individual animals may be represented in more than one cluster classification (column).   
bNo significant difference in proportion of each strain cluster isolated from NS and BAL 
(Fisher’s exact test, two sided: P = 0.91) 
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 3.4 Discussion  
   Mycoplasma bovis is associated with CPPS, a condition that is extremely difficult to treat 
and prevent. CPPS therefore, poses not only welfare concerns for the animals but high economic 
loss for the producer (Nicholas and Ayling, 2003). Prevalence studies have been conducted in 
Europe (Arcangioli, et al., Assié et al., 2009; Ayling et al., 2004; Bashiruddin et al., 2001; 
Blackburn et al., 2007; Le Grand et al., 2002;), Oceania (Ghadhersohi et al., 1999) and North 
American (Gagea et al., 2006, Wiggins et al., 2007); however, no studies have yet been 
conducted investigating the prevalence of M. bovis or assessing strain variation in western 
Canada. In this study the prevalence of M. bovis was examined in two different feedlots in 
Saskatchewan that source calves from all over western Canada. M. bovis prevalence varied 
between 41-68% of cattle tested in the commercial feedlot in the fall/winter of 2007 and between 
3-39% of the cattle tested at the University of Saskatchewan in fall/winter 2008. Thus high 
variation in prevalence occurred within a feedlot sampled at different times as well as between 
feedlots. The high variability observed in this study is not uncommon among prevalence studies 
(Allen et al., 1991, 1992; Catry, 2008; Rosendal and Martin et al., 1986; Thomas et al., 2002) 
and may reflect a number of factors.  
   The increase in M. bovis prevalence in the commercial feedlot may simply have been an 
effect of changes in prevalence associated with the sampling year as reported previously (Ayling 
et al., 2004; Blackburn et al., 2007). Alternatively, while University of Saskatchewan cattle 
showing the lower prevalence were asymptomatic, the commercial feedlot calves were treated 
for respiratory disease at their second sampling.  The majority of these treated animals required 
only one treatment with standard antibiotic therapy prior to recovery and none of the animals 
died of respiratory illness in the feedlot. Since M. bovis is resistant to most respiratory disease 
antibiotic therapies commonly used in feedlots and CPPS is characterized by its chronic state, the 
respiratory symptoms in these cattle successfully treated may be due to another bacteria, virus, or 
multiple pathogen complex (Francoz et al., 2005; Haines et al., 2001; Hirose et al., 2003; 
Rosenbusch et al., 2005; ter Laak et al., 1993). Recent studies have shown a positive relationship 
between M. bovis and other bacterial respiratory pathogens (Fulton et al., 2009; Poumarat, 2001). 
Therefore, while the higher prevalence of M. bovis recorded in the group treated for respiratory 
disease may not be connected to CPPS, it may be due to the presence of other respiratory 
pathogens.  
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   In the current study an increase in Mycoplasma, specifically M. bovis, colonization was 
observed with increased days on feed for cattle in both feedlots. There are several studies that 
indicate an increase in Mycoplasma colonization with days on feed (Allen et al., 1992; Rosendal 
and Martin et al., 1986). This increase may be due to the length of time the calves are exposed to 
shedders of Mycoplasma in the feedlot. In North American feedlots calves are purchased from 
cow-calf producers and fed in large pens sorted by age or size until an optimal weight is reached 
for sale to slaughter (Alexander et al., 1989; Ribble et al., 1995). It is common for North 
American feedlots to purchase cattle from several different sources at auction and often a single 
shipment of 60 or more calves to a feedlot can carry no more than two calves from the same 
source. This high rate of commingling with cattle from many sources has been found to be 
associated with an increased risk of developing lower respiratory disease in these cattle within 
the first few months on feed (Alexander et al., 1989; Fulton et al., 2009; Healy et al., 1993; 
Ribble et al., 1995). Therefore, time spent commingling with many other potential pathogen 
sources may affect the microbial status in the respiratory tract of a calf and may increase the 
chances of coming into contact with and being colonized by M. bovis, as was observed in this 
study.  
  Although M. bovis prevalence increased with days on feed, there was no agreement 
between the M. bovis status of an animal early in the feedlot and at later time points. This is 
primarily associated and consistent with the increase in M. bovis prevalence with days on feed 
such that many M. bovis negative animals on feedlot entry become positive. However, we also 
noted that while most M. bovis positive animals entering the feedlot remain M. bovis positive, 
several also clear the pathogen without treatment. Alternatively, the apparent clearance of M. 
bovis from a small number of animals may have been a false negative result. Indeed, sampling 
method affected the number of M. bovis isolates identified yielding variability in prevalence. In 
the current study the M. bovis prevalence was in fair agreement between nasal swabs (NS) and 
bronchoalveolar lavages (BAL) and while not significant, more M. bovis could be isolated from 
NS than BAL. There are several studies that have observed a significantly higher prevalence of 
M. bovis in NS than in BAL samples (Allen et al., 1992; Catry et al., 2008); however, one study 
found the opposite and recorded higher M. bovis prevalence from BAL than NS (Allen et al., 
1991). While the agreement between the two methods is fair based on the kappa statistic, further 
research with a greater number of animals may be needed to make significant conclusions 
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regarding which sampling method is a more accurate indicator of M. bovis prevalence and if 
either sampling method can be associated with disease outcome.  
   In the current study M. bovis was isolated in up to 25% of BAL samples from healthy 
University of Saskatchewan feedlot cattle. However, in a study in Belgium, M. bovis was not 
isolated from BAL in any of the healthy cattle sampled (Thomas et al., 2002). The investigators 
concluded that this indicated a small number of healthy carriers. Our results suggest a much 
higher number of potential carriers.  However, the variability between studies may also be due to 
differences in Mycoplasma culture and identification methodology or other factors such as 
geography and sampling year. While Thomas et al (2002), observed different M. bovis 
prevalence from the current study they did agree with the current findings that while one or two 
Mycoplasma spp. are generally predominant in the feedlot it is not uncommon for a single animal 
to harbour several species. In the present study no significant increase or decrease in the numbers 
of animals positive for multiple Mycoplasma spp. was observed with days on feed even when M. 
bovis prevalence increased in these animals. Interestingly however, in NS samples there was a 
numerical decline in M. bovirhinis positive animals as M. bovis positive animals increased with 
days on feed suggesting displacement. In contrast, the number of cattle positive for M. bovis and 
M. bovirhinis increased (non-significantly) in BAL with days on feed.  This observation suggests 
that while there may be some competition between closely related Mycoplasma spp. it is possible 
for them to coexist in the same animal.  
   The high prevalence of M. bovis in lung and joint samples from the necropsy animals 
with CPPS clinical pathology is in disagreement with Thomas et al (2002) in which relatively 
few necropsy animals appeared to be colonized by M. bovis. In the current study samples were 
only taken at necropsy if lung pathology associated with CPPS and septic arthritis was observed, 
while in the Thomas et al (2002) study  samples were taken from animals at necropsy with little 
differentiation between M. bovis associated pathology and other types of pneumonias. Therefore, 
the mortalities in these previous reports may be more commonly due to other respiratory 
pathogens.  
   Molecular strain differentiation methods distinguish between strains based on variability 
in nucleotide sequence within the whole genome. Given isolation of M. bovis from healthy 
animals, one of the objectives of the current study was to identify genetic variation in M. bovis 
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by employing molecular strain differentiation to compare populations in CPPS afflicted and 
healthy cattle.  Such a comparison could identify virulent and avirulent strains. 
   There are several molecular methods for M. bovis strain differentiation currently 
described in the literature with varying degrees of specificity, sensitivity, reproducibility, speed, 
technical and labour requirements (Beier et al., 1998; Biddle et al., 2005; Butler et al., 2001; Fox, 
2008; Kusiluka et al., 2000; McAuliffe et al., 2004; McAuliffe et al., 2008; Miles et al., 2005). 
Originally RAPD was chosen as a seemingly ideal method of strain differentiation for this study 
as previous literature had found RAPD to be as sensitive and specific as other methods, but with 
fewer technical and time requirements (McAuliffe et al., 2004, Williams et al., 1990). However, 
in the current study, RAPD methodology showed extremely poor reproducibility even in the 
appearance of major bands visualized with ethidium bromide under UV light. Previous research 
did cite some reproducibility problems, but it appeared even with modifications to the original 
protocols the reproducibility was much lower than anticipated from this earlier research (Cherry 
et al., 2006; Cousin-Allery et al., 2000; Feberwee et al., 2005; Mettifogo et al., 2006; McAuliffe 
et al., 2004; Stakenborg et al., 2006). The low reproducibility made RAPD an unreliable method 
for strain differentiation in this study. AFLP methodology employed here was based on 
Kokotovic et al (1999) and produced reproducible banding patterns with greater than 92% 
similarity score based on dice coefficient values for duplicate determinations. While this 
reproducibility is somewhat less than the identical densitometric curves reported by Kokotovic et 
al (1999) when duplicate samples were analyzed, the result is not surprising given the relatively 
complex multi-step AFLP protocol.    
   Clustering of AFLP banding patterns for M. bovis  isolates cultured from lung and joint 
samples at necropsy, identified three main clusters (A, B and C) for which dice coefficient values 
were less than 75%, well below the 92% value observed for duplicate samples. The necropsy 
samples came from ten different feedlots in Alberta and Saskatchewan; therefore, represent a 
geographically diverse group. Comparable studies in which M. bovis strain identification was 
conducted found similar results in that relatively few distinct clusters were identified in cattle 
from a diverse geographical sampling (Kusiluka et al., 2002; McAuliffe et al., 2004).   
   All necropsy samples were isolated from CPPS mortalities that occurred within a year of 
one another; therefore, no inferences can be made about M. bovis strain and sampling year in this 
group. Six of the ten feedlots in which CPPS mortalities were sampled had only one 
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representative necropsy animal; therefore, statistically significant conclusions cannot be made 
regarding the trend between geographical location and M. bovis strains present in this group. 
However, of the four feedlots in which more than one CPPS mortality was sampled, two to three 
M. bovis strains were isolated in three, suggesting that geographical location within western 
Canada was not a factor in M. bovis strains isolated. The present study indicated that the lung or 
joint of a single animal at necropsy could be colonized by multiple M. bovis strains. While only 
seven animals had data for both lung and joint samples, multiple strains could be identified in a 
single tissue for two of these animals and a different strain was isolated from the lung than from 
the joint in three of these animals. There is literature to support both the isolation of the same 
strain in multiple body sites (Fox et al., 2008)and the isolation of genetically distinct M. bovis 
strains from different body sites within a single animal (Biddle et al., 2005). Further research 
with strain differentiation in multiple body sites from larger groups of animals may provide a 
better understanding of this strain discrepancy within and between sampling locations   
   When the strains from cattle at both the University and commercial feedlots were 
compared to the strains identified in the necropsy animals no new strain clusters were identified. 
The strains identified in the commercial feedlot in 2006 from cattle treated for respiratory disease 
clustered mainly with group A while the strains identified in the University of Saskatchewan 
feedlot in 2007 from clinically healthy cattle clustered mainly with necropsy cluster B with some 
isolates clustering with strain group A. Since none of the cattle in the University of 
Saskatchewan or commercial feedlots presented with CPPS the A and B strains might be 
considered of low virulence.  
   The differences in strain prevalence between the two groups may be due to the years in 
which the samples were collected. The predominant Mycoplasma spp. cultured from cattle varies 
year to year so it is possible that the principal strains of these species also vary between year 
(Ayling et al., 2004; Blackburn et al., 2007).  However, the tissues cultured from the animals at 
necropsy were all collected within a one year period between the conduct of the commercial 
feedlot study and the University of Saskatchewan feedlot study. Therefore, sampling year is 
likely not the sole cause of the strain diversity between these two feedlots. Another possible 
explanation for the strain discrepancy between the two feedlots is geography; however, these 
feedlots are both located within Saskatchewan and both purchase calves from numerous sources 
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so this is unlikely. Furthermore, no trends between geographical location of sampling and M. 
bovis strains isolated were observed in the necropsy group.    
   Mycoplasma bovis isolates clustering in strain C were not found in healthy cattle 
suggesting this could be a virulent strain. However, the B and C strains were of lowest 
prevalence in lung and joint tissue of necropsy animals compared to the A strain found in 71% of 
lung samples and all joint samples. Thus, the link between molecular strain differentiation and 
pathogenicity is still unclear. Our failure to identify a unique strain(s) associated with clinical 
CPPS could be due to variable host response or the presence or absence of other bacteria in a 
multifactorial scenario. However, studies have shown that M. bovis strains cultured from cattle 
with M. bovis associated disease are capable of causing disease when inoculated into both 
conventional and gnotobiotic calves (Allen et al., 1992; Arcangioli et al., 2007; Haines et al., 
2001; Khodakaram-Tafti and López, 2001; Poumarat et al., 2001). Several recent studies have 
demonstrated that much of the genetic variation between M. bovis isolates is in repetitive non-
coding regions of the genome (McAuliffe et al., 2008; Miles et al., 2005). The differentiations 
made by molecular strain typing techniques may not cluster the isolates by expressed genes; 
therefore, may not be sensitive enough to differentiate strains based on virulence. In a recent 
study of Mycoplasma gallisepticum, a respiratory pathogen in poultry, RAPD molecular strain 
typing was comparable with strain differentiation based on sequence polymorphisms when 
potential pathogen associated genes were amplified (Ferguson et al., 2005). Although the 
methods were comparable, RAPD demonstrated much lower discriminatory power in 
differentiating between vaccine strains and pathogenic field strains, than sequence analysis of 
expressed genes. Therefore, strain identification based on developing whole-genome fingerprints 
without previous knowledge of the genome may be less discriminatory and efficient in 
differentiating between virulent and avirulent M. bovis strains. Perhaps virulence factor typing 
and further strain differentiation within these AFLP based clusters via functional gene 
sequencing could further explain the differences between disease outcomes within the three 
identified clusters.  
   This study also found no significant differences between the distribution of strains 
isolated from NS and BAL samples. This is contrary to reported variations in adherence ability 
among isolates taken from different tissues (Sachse et al., 1993; Thomas et al., 2003). 
Furthermore, the higher prevalence of M. bovis in NS compared to BAL as observed here and by 
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others, is consistent with the presence of unique strains capable of colonizing the lower 
respiratory tract (Allen et al., 1992; Catry et al., 2008). The finding of all three strains in BAL in 
the present study suggests; however, the difference in M. bovis colonization between the upper 
and lower respiratory tract is host dependent. 
   In conclusion we isolated M. bovis from 93% of lung and 77% of joint tissues collected 
post mortem from cattle with clinical presentations consistent with CPPS and consistent with the 
identification of this organism as the causative agent. We were also able to isolate M. bovis from 
the upper and lower respiratory tract of healthy cattle. Consistent with reports from other 
geographical regions, the prevalence of M. bovis was significantly higher in the upper compared 
to lower respiratory tract and increased in both tract locations with days on feed.  Two of the 
three strain clusters identified with AFLP in the CPPS clinical presentation group were also 
isolated from healthy animals and those with respiratory disease presentations unrelated to 
CPPS. No meaningful associations could be derived regarding the ability to colonize the lower 
respiratory tract, the development of CPPS, geographical location of samplings, year of 
samplings and M. bovis strain clusters. This could reflect a limitation of AFLP methodology to 
detect genetic variation associated virulence. Alternatively our results suggest that following M. 
bovis colonization of the respiratory tract, whether the animal clears this pathogen or develops 
CPPS is dependent on host factors and/or the presence of secondary pathogens. 
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4.0 GENERAL DISCUSSION AND CONCLUSIONS 
   The control of M. bovis associated disease has many challenges. Resistance to most 
antibiotics makes treatment difficult (Francoz et al., 2005; Gerchman et al., 2009; Hirose et al., 
2003; Rosenbusch et al., 2005; ter Laak et al., 1993; Vogel et al., 2001) and the variability of the 
surface antigens hinders development of efficacious vaccines (Behrens et al., 1996, Le Grand et 
al., 1996, Lysnyansky et al., 1996). The nature of the feedlot system in North America allows 
rapid efficient spread of the respiratory disease pathogens including M. bovis (Alexander et al., 
1989; Fulton et al., 2009; Healy et al., 1993; Ribble et al., 1995). Once an animal develops 
pneumonia the immune modulation and evasion characteristics of M. bovis appear to aid the 
chronic disease state and systemic spread to multiple joints that defines Chronic Pneumonia and 
Polyarthritis syndrome (Butler et al., 2001; Krysak, 2006; Pourmat et al., 2001; Arcangioli et al., 
2007). 
   The prevalence of M. bovis in feedlots has been studied in most first world nations with 
beef production; however, due to differences in geography, sample type, sampling period and 
identification methods the numbers are not comparable to one another and are therefore, not 
applicable to western Canada (Arcangioli, et al., Assié et al., 2009; Ayling et al., 2004;  2007; 
Bashiruddin et al., 2001; Blackburn et al., 2007; Ghadhersohi et al., 1999;  Gagea et al., 2006; Le 
Grand et al., 2002; Wiggins et al., 2007). The present study was the first M. bovis prevalence 
study in western Canadian feedlots and results were consistent with previous work in that 
prevalence varied considerably between feedlots and years and increased with days on feed. 
Increased prevalence was not unexpected as the more time calves are commingled with other 
cattle from multiple sources the more likely they are to transfer or acquire pathogens such as M. 
bovis (Alexander et al., 1989; Fulton et al., 2009; Healy et al., 1993; Ribble et al., 1995). There 
was also a higher prevalence in the nasal swabs than in bronchoalveolar lavages, which was also 
not unexpected from similar studies previously published (Allen et al., 1992; Catry et al., 2008).  
Therefore, nasal swabs may overestimate M. bovis prevalence in the lower lung. As CPPS is a 
condition of the lower respiratory tract BAL is presumably a more accurate predictor of CPPS. It 
was also observed that while animals positive for M. bovis upon entry did seem to be able to 
spread the bacteria to other animals, as seen by the increased prevalence with days on feed, some 
of these animals appeared to be able to clear the infection as they were found negative for M. 
bovis when sampled again later. This was also true for animals in which M. bovis could be 
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isolated from the lower respiratory tract with BAL sampling. Therefore, isolation of M. bovis 
from the lower respiratory tract is not the only predictor of CPPS development and strain 
variation, environmental or host factors must also play a role. It should be noted that while BAL 
uses alchol sterilized endoscopes and tubing some transfer of bacteria from the nasal passage to 
the lower lungs during the BAL sampling process is possible. Furthermore, because 
Mycoplasmas are also so slow growing and fastidious subculturing and enrichment are often 
utilized, as was the case in this study, and this could allow for some false positive BAL results. 
Future research regarding BAL and culture protocols may be of benefit to ensure the reliability 
of BAL prevalence recorded. 
Several genomic based strain differentiation methods have been tested with Mycoplasma 
species; however, the reproducibility, sensitivity and congruence between different methods is 
still unclear (Beier et al., 1998; Biddle et al., 2005; Butler et al., 2001; Fox, 2008; Kusiluka et al., 
2000; McAuliffe et al., 2004; McAuliffe et al., 2008; Miles et al., 2005).  In the current study we 
attempted RAPD strain differentiation but observed undesirably low reproducibility. When 
duplicate samples were analyzed with identical RAPD protocols and reagents the results varied 
considerably in both success of the reaction and resultant banding patterns when successful 
reactions could be obtained. It is likely that high variability in the annealing sites of the low 
specificity random primer (10mer) caused this high variation in banding patterns between runs. 
Therefore, the RAPD protocol was deemed inappropriate for this study as statistically significant 
and reliable results would not have been possible.  
One of the significant challenges we experienced in M. bovis strain differentiation was in 
part associated with the quantity, quality and/or stability of DNA. The DNA extracted from M. 
bovis samples did not appear to be stable even when high quality extraction kits were utilized 
and resultant DNA was stored at -80°C. One suggestion was that our extraction procedures 
produced high quantities of RNA, which might also be detected by UV spectrophotmetric 
quantification, but which is much more susceptible to degradation compared to DNA. However, 
the addition of an RNAase step did not alter the DNA yield or reduce the loss of DNA after 
freezing and thawing.   Eventually we employed a whole genome amplification step to produce 
enough DNA to permit strain differentiation. Quantification of amplified DNA was then 
performed with picogreen to ensure that only double stranded DNA was quantified. While high 
quantity DNA was obtained with this method we rapidly proceeded with AFLP strain 
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differentiation due to concerns that the DNA quantities would still decrease over time. Therefore, 
the stability of this amplified DNA was never tested at a later time point and further study of the 
degradation of Mycoplasma DNA extracted with high-quality kits should be conducted.  
When AFLP was utilized post genome amplification the reproducibility and reliability of 
the assay was far improved and duplicate results appeared consistent even when separate 
amplifications of the same sample were utilized. The use of specific restriction enzymes in 
combination with specific primers and analysis with capillary electrophoresis, which is 
automated and reliable, are thought to be the reasons for improved reproducibility and reliability 
of AFLP.  However, AFLP also required some manipulation from the original protocols 
(Kokotovic et al., 1999) including increasing the incubation periods for the restriction enzyme 
digest and adapter annealing steps as well as increasing the concentration of double stranded 
adapters used. While the reproducibly of AFLP was adequate in our hands to differentiate 
clusters of M. bovis, we did not achieve the 100% reproducibility reported by Kokotovic et al 
(1999).  It is possible that we could achieve 100% reproducibility with additional assay 
experience; however, given the complexity of the multistep protocol this would be a very high 
expectation.    
Upon analysis with capillary electrophoresis the data often included cross-over peaks 
from the size standard, which were removed as they were common in all samples. This may have 
camouflaged peaks from the sample in the same size range and possibly decreased the sensitivity 
of the reaction. Large peaks visualized on the densitometric curve were also often labelled two 
peaks within 5 bp differences; therefore, the data needed to be manually manipulated and 
normalized for these peaks in all samples before being analyzed with the Bionumerics software, 
which proved extremely awkward in this capacity. The manual manipulation required to define 
bands and the numerous options for settings such as position tolerances create a high potential 
for over manipulation by researchers. There are to date no regulations on settings and 
manipulation for genomic fingerprints analyzed with Bionumerics; therefore, study comparisons 
at this point may be of little value. Certainly investigators should report their settings for all the 
parameters that can be manipulated using this software tool. 
Using the successful AFLP protocols three clusters could be identified in 19 necropsy 
animals from ten feedlots. No relationship could be found between AFLP cluster, and disease 
outcome, body site from sampling, geographical sampling location or sampling period. 
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Therefore, it appears that our original hypothesis that one strain is responsible for CPPS in 
feedlot cattle is disproved. However, these clusters represent differences in the whole genome 
and probably differentiate based on polymorphisms in both the non-coding and functional gene 
regions. Therefore, whether we label these clusters as strains depends on whether a strain is 
defined as being morphologically, physiologically, or genetically different. In epidemiology 
studies such as this one, physiological differences specifically relating to virulence are of interest 
when defining strains. Therefore, further studies to identify and compare expressed virulence 
genes in these clusters would help us determine whether pathogenicity varies within or between 
these clusters and further test our original hypothesis when strains are defined based on 
physiological diversity. Koch’s postulates state that a supposed pathogen must cause disease 
when reinfected into the host. Therefore, reinfecting cattle with representatives of the three strain 
clusters identified in the current study may also help determine the virulence of these clusters.    
As two of the clusters identified in CPPS mortalities were also found in CPPS free cattle 
it could be assumed that the difference in disease outcome was at least in part due to factors other 
than strain. The immune response of the host may affect the outcome of M. bovis colonization. 
Immunohistochemical staining has been conducted to examine the host response in CPPS 
afflicted cattle; however, a comparison of expressed immune factors in asymptomatic shedders 
of M. bovis and those with M. bovis associated diseases has not been conducted. Monitoring 
immune indicators as determined by antibody titres, immunhistochemistry of lung and joint 
samples,   and/or gene expression profiles of immune factors in animals colonized with M. bovis 
as they develop CPPS compared to animals colonized by M. bovis that remain asymptomatic 
may reveal host immune responses indicative of disease progression.  The microbial population 
in the respiratory tract may also affect the outcome of M. bovis colonization. While M. bovis has 
been observed to correspond to other respiratory pathogens, studies comparing the microbial 
populations in cattle that develop CPPS from M. bovis colonization and those that remain healthy 
has not been conducted. Studies to investigate the role of other Mycoplasmas may also be of 
relevance as closely related species are often of the highest competition as environmental 
requirements are likely close. Comparative studies to determine differences in host immune 
status and microbial environment may further our current understanding of the factors involved 
in the development of CPPS.   
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We had originally anticipated much higher numbers of CPPS as local veterinarians had 
suggested that in previous years 25% of fall-placed feedlot calves developed undifferentiated 
fever and 5% of these animals died or were euthanized due to CPPS. We had planned a study to 
track the M. bovis strains in animals that developed CPPS in the feedlot to compare with a group 
of animals that remained healthy as a control based on these original estimates. When in the first 
year there were no animals developing pneumonias characteristic of CPPS a second sampling 
year was conducted at the University of Saskatchewan feedlot as a comparison and in hopes that 
more CPPS animals would be identified. When there was a lack of CPPS in this second sampling 
year it was decided that the necropsy samples would have to suffice as our CPPS group although 
this group was also smaller than originally anticipated due to low disease prevalence.  Our 
inability to conduct the original study design limited our ability to determine the factors 
indicative of CPPS development in the feedlot. A comparison of the three AFLP clusters 
identified in this necropsy group with clusters in animals as they develop CPPS in the feedlot 
would be a beneficial future study to determine if this population changes over time and further 
investigate our original hypothesis that one M. bovis strain is responsible for CPPS in feedlot 
cattle.  
Overall, we were unable to support or reject our original hypothesis using the current 
sample set and molecular methodologies. Although we could not identify specific pathogenic M. 
bovis strains, we could not rule out the possibility that AFLP was not able to detect genetic 
variation specifically associated with virulence. The fact that healthy animals harbouring M. 
bovis in the lower respiratory tract were able to clear this pathogen clearly suggests that host or 
other environmental factors (other pathogens) are key factors in disease progression.  
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